<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical and oral steroids for otitis media with effusion (OME) in children - Mulvaney, CA - 2023 | Cochrane Library</title> <meta content="Topical and oral steroids for otitis media with effusion (OME) in children - Mulvaney, CA - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015255.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical and oral steroids for otitis media with effusion (OME) in children - Mulvaney, CA - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015255.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015255.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topical and oral steroids for otitis media with effusion (OME) in children" name="citation_title"/> <meta content="Caroline A Mulvaney" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Kevin Galbraith" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Katie E Webster" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Mridul Rana" name="citation_author"/> <meta content="Frimley Health NHS Foundation Trust" name="citation_author_institution"/> <meta content="Rachel Connolly" name="citation_author"/> <meta content="National Institute for Health and Care Excellence" name="citation_author_institution"/> <meta content="Ben Tudor-Green" name="citation_author"/> <meta content="University Hospitals Plymouth NHS Trust" name="citation_author_institution"/> <meta content="Tal Marom" name="citation_author"/> <meta content="Samson Assuta Ashdod University Hospital, Ben Gurion University Faculty of Health Sciences" name="citation_author_institution"/> <meta content="Mat Daniel" name="citation_author"/> <meta content="Nottingham Children's Hospital" name="citation_author_institution"/> <meta content="Roderick P Venekamp" name="citation_author"/> <meta content="University Medical Center Utrecht, Utrecht University" name="citation_author_institution"/> <meta content="Anne GM Schilder" name="citation_author"/> <meta content="Samuel MacKeith" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="samuel.mackeith@ouh.nhs.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD015255.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/12/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015255.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015255.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015255.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Intranasal; Adrenal Cortex Hormones [therapeutic use]; *Anti-Bacterial Agents [therapeutic use]; *Otitis Media with Effusion [drug therapy]; Steroids [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015255.pub2&amp;doi=10.1002/14651858.CD015255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015255\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015255\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","th","ms","fa","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015255.pub2",title:"Topical and oral steroids for otitis media with effusion (OME) in children",firstPublishedDate:"Dec 13, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane ENT Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015255.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015255.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015255.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015255.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015255.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015255.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015255.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015255.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015255.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015255.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2502 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015255.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-sec-0136"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-sec-0126"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/appendices#CD015255-sec-0142"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/supinfo/CD015255-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/supinfo/CD015255-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical and oral steroids for otitis media with effusion (OME) in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0004">Caroline A Mulvaney</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0005">Kevin Galbraith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0006">Katie E Webster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0007">Mridul Rana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0008">Rachel Connolly</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0009">Ben Tudor-Green</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0010">Tal Marom</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0011">Mat Daniel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0012">Roderick P Venekamp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0013">Anne GM Schilder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information#CD015255-cr-0014"><i class="icon corresponding-author fa fa-envelope"></i>Samuel MacKeith</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information/en#CD015255-sec-0147">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 December 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015255.pub2">https://doi.org/10.1002/14651858.CD015255.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015255-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015255-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015255-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015255-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015255-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD015255-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015255-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015255-abs-0001" lang="en"> <section id="CD015255-sec-0001"> <h3 class="title" id="CD015255-sec-0001">Background</h3> <p>Otitis media with effusion (OME) is an accumulation of fluid in the middle ear cavity, common amongst young children. The fluid may cause hearing loss. Although most episodes of OME in children resolve spontaneously within a few months, when persistent it may lead to behavioural problems and a delay in expressive language skills. Management of OME includes watchful waiting, medical, surgical and other treatments, such as autoinflation. Oral or topical steroids are sometimes used to reduce inflammation in the middle ear. </p> </section> <section id="CD015255-sec-0002"> <h3 class="title" id="CD015255-sec-0002">Objectives</h3> <p>To assess the effects (benefits and harms) of topical and oral steroids for OME in children. </p> </section> <section id="CD015255-sec-0003"> <h3 class="title" id="CD015255-sec-0003">Search methods</h3> <p>We searched the Cochrane ENT Register, CENTRAL, Ovid MEDLINE, Ovid Embase, Web of Science, ClinicalTrials.gov, ICTRP and additional sources for published and unpublished studies on 20 January 2023. </p> </section> <section id="CD015255-sec-0004"> <h3 class="title" id="CD015255-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐randomised trials in children aged 6 months to 12 years with unilateral or bilateral OME. We included studies that compared topical or oral steroids with either placebo or watchful waiting (no treatment). </p> </section> <section id="CD015255-sec-0005"> <h3 class="title" id="CD015255-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes, determined by a multi‐stakeholder prioritisation exercise, were: 1) hearing, 2) OME‐specific quality of life and 3) systemic corticosteroid side effects. Secondary outcomes were: 1) presence/persistence of OME, 2) other adverse effects (including local nasal effects), 3) receptive language skills, 4) speech development, 5) cognitive development, 6) psychosocial outcomes, 7) listening skills, 8) generic health‐related quality of life, 9) parental stress, 10) vestibular function and 11) episodes of acute otitis media. We used GRADE to assess the certainty of evidence. </p> <p>Although we included all measures of hearing assessment, the proportion of children who returned to normal hearing was our preferred method to assess hearing, due to challenges in interpreting the results of mean hearing thresholds. </p> </section> <section id="CD015255-sec-0006"> <h3 class="title" id="CD015255-sec-0006">Main results</h3> <p>We included 26 studies in this review (2770 children). Most studies of oral steroids used prednisolone for 7 to 14 days. Studies of topical (nasal) steroids used various preparations (beclomethasone, fluticasone and mometasone) for between two weeks and three months. All studies had at least some concerns regarding risk of bias. Here we report our primary outcomes and main secondary outcome, at the longest reported follow‐up. </p> <p><b>Oral steroids compared to placebo</b> </p> <p>Oral steroids probably result in little or no difference in the proportion of children with normal hearing after 12 months (69.7% of children with steroids, compared to 61.1% of children receiving placebo, risk ratio (RR) 1.14, 95% confidence interval (CI) 0.97 to 1.33; 1 study, 332 participants; moderate‐certainty evidence). There is probably little or no difference in OME‐related quality of life (mean difference (MD) in OM8‐30 score 0.07, 95% CI ‐0.2 to 0.34; 1 study, 304 participants; moderate‐certainty evidence). </p> <p>Oral steroids may reduce the number of children with persistent OME at 6 to 12 months, but the size of the effect was uncertain (absolute risk reduction ranging from 13.3% to 45%, number needed to treat (NNT) of between 3 and 8; low‐certainty evidence). The evidence was very uncertain regarding the risk of systemic corticosteroid side effects, and we were unable to conduct any meta‐analysis for this outcome. </p> <p><b>Oral steroids compared to no treatment</b> </p> <p>Oral steroids may result in little or no difference in the persistence of OME after three to nine months (74.5% children receiving steroids versus 73% of those receiving placebo; RR 1.02, 95% CI 0.89 to 1.17; 2 studies, 258 participants; low‐certainty evidence). The evidence on adverse effects was very uncertain. We did not identify any evidence on hearing or disease‐related quality of life. </p> <p><b>Topical (intranasal) steroids compared to placebo</b> </p> <p>We did not identify data on the proportion of children who returned to normal hearing. However, the mean change in hearing threshold after two months was ‐0.3 dB lower (95% CI ‐6.05 to 5.45; 1 study, 78 participants; very low‐certainty evidence). The evidence suggests that nasal steroids make little or no difference to disease‐specific quality of life after nine months (OM8‐30 score, MD 0.05 higher, 95% CI ‐0.36 to 0.46; 1 study, 82 participants; low‐certainty evidence). </p> <p>The evidence is very uncertain regarding the effect of nasal steroids on persistence of OME at up to one year. Two studies reported this: one showed a potential benefit for nasal steroids, the other showed a benefit with placebo (2 studies, 206 participants). The evidence was also very uncertain regarding the risk of corticosteroid‐related side effects, as we were unable to provide a pooled effect estimate. </p> <p><b>Topical (intranasal) steroids compared to no treatment</b> </p> <p>We did not identify data on the proportion of children who returned to normal hearing. However, the mean difference in final hearing threshold after four weeks was 1.95 dB lower (95% CI ‐3.85 to ‐0.05; 1 study, 168 participants; low‐certainty evidence). Nasal steroids may reduce the persistence of OME after eight weeks, but the evidence was very uncertain (58.5% of children receiving steroids, compared to 81.3% of children without treatment, RR 0.72, 95% CI 0.57 to 0.91; 2 studies, 134 participants). We did not identify any evidence on disease‐related quality of life or adverse effects. </p> </section> <section id="CD015255-sec-0007"> <h3 class="title" id="CD015255-sec-0007">Authors' conclusions</h3> <p>Overall, oral steroids may have little effect in the treatment of OME, with little improvement in the number of children with normal hearing and no effect on quality of life. There may be a reduction in the proportion of children with persistent disease after 12 months. However, this benefit may be small and must be weighed against the potential for adverse effects associated with oral steroid use. </p> <p>The evidence for nasal steroids was all low‐ or very low‐certainty. It is therefore less clear if nasal steroids have any impact on hearing, quality of life or persistence of OME. Evidence on adverse effects was very limited. </p> <p>OME is likely to resolve spontaneously for most children. The potential benefit of treatment may therefore be small and should be balanced with the risk of adverse effects. Future studies should aim to determine which children are most likely to benefit from treatment, rather than offering interventions to all children. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015255-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015255-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015255-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015255-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015255-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015255-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD015255-abs-0014">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015255-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD015255-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015255-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015255-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015255-abs-0002" lang="en"> <h3>Oral or nasal steroids for otitis media with effusion (OME or 'glue ear') in children</h3> <p><b>Key messages</b> </p> <p>Taking steroids in tablet or syrup form (by mouth) may have little or no impact on hearing and quality of life for children with glue ear. Steroids may reduce the number of children who have glue ear after 6 to 12 months, but we are uncertain how large this reduction might be. </p> <p>Using a steroid nasal spray may also make little or no difference to hearing or quality of life, although the evidence is not as robust. It is also unclear whether nasal steroids affect the number of children with glue ear after longer‐term follow‐up. </p> <p>Due to a lack of robust evidence, it is difficult to know how many people might suffer from harm from these treatments. However, when oral steroids are used for other conditions and for a prolonged period of time, they may cause side effects such as bone loss. This potential for harm should be considered when deciding whether or not to use these treatments. </p> <p><b>What is OME?</b> </p> <p>Glue ear (or 'otitis media with effusion', OME) is a common condition affecting young children. Fluid collects in the middle ear, causing hearing impairment. As a result of their poor hearing, children may have behavioural difficulties and delays in their speech development. </p> <p><b>How is OME treated?</b> </p> <p>Most of the time, OME does not need any treatment and the symptoms will get better with time. In children with persistent OME, different treatments have been explored, including medications or surgery. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out whether steroids were better than placebo (sham or dummy treatment) or no treatment for children with OME. </p> <p>We also wanted to see if there were any unwanted effects associated with taking steroids.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared steroids taken as a tablet or nasal spray with placebo or no treatment in children with OME. We compared and summarised the study results, and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 26 studies, including 2770 children.</p> <p><i>Oral steroids compared to placebo</i> </p> <p>We found that oral steroids probably make little or no difference to the number of children who have normal hearing after one year of follow‐up. Normal hearing was seen in 69.7% of children who received steroids and 61.1% of children who received placebo. There is also likely to be very little or no difference between the two groups in quality of life (related to glue ear). </p> <p>The evidence suggests that oral steroids might reduce the number of children who have glue ear after 6 to 12 months of follow‐up, but the results from the studies were very different ‐ so we do not know how big the reduction might be. The evidence on side effects of oral steroids was not robust. From the evidence in this review we were not able to determine what the chance of side effects would be. </p> <p><i>Oral steroids compared to no treatment</i> </p> <p>We found fewer studies here, and there was no information on hearing or quality of life. After up to nine months, there may be little or no difference in the number of children who still have glue ear (74.5% of children who received steroids, compared to 73% of those who received no treatment). Again, the evidence on side effects was not robust. </p> <p><i>Nasal steroids compared to placebo</i> </p> <p>We are unsure whether nasal steroids have any effect on hearing, as the evidence was not robust. Nasal steroids may make little or no difference to quality of life after nine months of follow‐up. We are uncertain whether nasal steroids affect the number of children with persistent glue ear at up to one year, as the evidence from two studies was conflicting. We are not sure whether there may be a risk of harm with this treatment, as the studies did not clearly report side effects. </p> <p><i>Nasal steroids compared to no treatment</i> </p> <p>We only have information on hearing at up to four weeks of follow‐up, which may not be long enough to really assess this treatment. However, at this stage, there might be little or no difference in hearing between children who receive nasal steroids or no treatment. We are also unsure whether nasal steroids affect the number of children with persistent glue ear after eight weeks. We did not identify any information on quality of life or side effects of treatment from these studies. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The studies used lots of different types of medication, for different lengths of time. We do not know if some of these may be more effective than others. We do not have good evidence on side effects of these treatments, but they may cause problems for some children. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is up‐to‐date to January 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015255-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015255-sec-0136"></div> <h3 class="title" id="CD015255-sec-0137">Implications for practice</h3> <section id="CD015255-sec-0137"> <p>Oral steroids may slightly reduce the presence/persistence of otitis media with effusion (OME) in children in the medium term when compared to placebo, and they probably result in little to no effect on hearing and quality of life. Their impact in the longer term is less certain. </p> <p>The evidence for topical (intranasal) steroids is also uncertain. Topical (intranasal) steroids may have little or no effect on hearing and disease‐related quality of life, and the effect on presence/persistence of OME is unclear. </p> <p>The evidence on the risk of adverse effects with oral or topical steroids identified by this Cochrane Review is very uncertain and is likely to depend on the route of administration and duration of treatment. Although the data available in this review are limited, the use of oral steroids (especially prolonged or repeated courses) may cause potential adverse effects, such as osteoporosis or growth retardation. The potential for harm should thus always be considered when deciding on a treatment strategy. </p> </section> <h3 class="title" id="CD015255-sec-0138">Implications for research</h3> <section id="CD015255-sec-0138"> <p>This review forms part of a suite of five reviews that consider interventions for OME (<a href="./references#CD015255-bbs2-0070" title="GalbraithK , MulvaneyCA , MacKeithS , MaromT , DanielM , VenekampRP , et al. Autoinflation for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015253. [DOI: 10.1002/14651858.CD015253]">Galbraith 2022</a>; <a href="./references#CD015255-bbs2-0086" title="MacKeithS , MulvaneyCA , GalbraithK , MaromT , DanielM , VenekampRP , et al. Adenoidectomy for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015252. [DOI: 10.1002/14651858.CD015252]">MacKeith 2022a</a>; <a href="./references#CD015255-bbs2-0087" title="MacKeithS , MulvaneyCA , GalbraithK , MaromT , DanielM , VenekampRP , et al. Ventilation tubes (grommets) for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015215. [DOI: 10.1002/14651858.CD015215]">MacKeith 2022b</a>; <a href="./references#CD015255-bbs2-0093" title="MulvaneyCA , GalbraithK , MacKeithS , MaromT , DanielM , VenekampRP , et al. Antibiotics for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015254. [DOI: 10.1002/14651858.CD015254]">Mulvaney 2022a</a>; <a href="./references#CD015255-bbs2-0119" title="MulvaneyCA , GalbraithK , MacKeithS , MaromT , DanielM , VenekampRP , et al. Topical and oral steroids for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015255. [DOI: 10.1002/14651858.CD015255]">Mulvaney 2022b</a>). Here we present implications for research in this field, which are shared across the suite of reviews: </p> <p> <ul id="CD015255-list-0031"> <li> <p>As OME is a fluctuating condition with high rates of resolution and recurrence, and a highly variable impact on children, clinical trials (and, in particular, randomised controlled trials) may not be the research design of choice. Instead, evidence may be better obtained from surgical or clinical registries (for example, see <a href="./references#CD015255-bbs2-0108" title="SchmalbachCE , BreretonJ , BowmanC , DennenyJC . American Academy of Otolaryngology–Head and Neck Surgery/Foundation Reg-ent Registry: Purpose, properties, and priorities. Otolaryngology – Head and Neck Surgery2021;164(5):964-71.">Schmalbach 2021</a>) or prospective cohort studies, with the use of 'big data'. These data sets may also be used to help identify subgroups of children who are at greater risk of persistent disease or long‐term consequences of OME. A clearer understanding of possible subgroups of children is needed to better target interventions to those who need them most, whilst avoiding over‐treatment for those in whom spontaneous resolution is anticipated. </p> </li> <li> <p>Adverse effects of interventions are important, and should always be assessed. However, randomised controlled trials are also not the best method to consider these ‐ especially when events are rare. Observational studies with longer follow‐up and larger numbers of participants are needed to provide more robust evidence on the frequency of side effects. It is important to note that the protocol, inclusion criteria and search strategy used for this review would have excluded these types of studies. It is therefore possible that evidence of this type may exist. With this in mind, we would advocate a review of observational data, to assess whether evidence regarding longer‐term outcomes and adverse events is already available. This may be particularly important when assessing harms from serious but rare adverse events. </p> </li> <li> <p>It is encouraging that a core outcome set has been developed in this field (<a href="./references#CD015255-bbs2-0063" title="BruceI , HarmanN , WilliamsonP , TierneyS , CalleryP , MohiuddinS , et al. The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. Health Technology Assessment2015;19(68):1-374. [DOI: 10.3310/hta19680]">Bruce 2015</a>; <a href="./references#CD015255-bbs2-0085" title="LiuPZ , Ismail-KochH , StephensonK , DonneAJ , FergieN , DerryJ , et al. A core outcome set for research on the management of otitis media with effusion in otherwise-healthy children. International Journal of Pediatric Otorhinolaryngology2020;134:110029. [DOI: 10.1016/j.ijporl.2020]">Liu 2019</a>). Guidance on <i>how</i> to measure the different outcomes would also be helpful for future research. </p> </li> <li> <p>Comparison of mean hearing thresholds is widely used in research to assess the impact of different interventions on hearing. However, this outcome measure risks underestimating the potential impact of interventions on hearing. Small changes in mean hearing thresholds may be consistent with a substantial improvement in the number of children whose hearing returns to normal ‐ particularly in a condition with a high spontaneous resolution rate. We would encourage researchers to assess hearing with the proportion of children in whom hearing returns to normal, in preference to mean hearing thresholds. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015255-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015255-sec-0008"></div> <div class="table" id="CD015255-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral steroids compared to placebo for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Oral steroids compared to placebo for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children aged 6 months to 12 years with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> oral steroids <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With oral steroid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing ‐ return to normal hearing</p> <p>Follow‐up: 12 months (medium‐term)</p> <p>№ of participants: 332 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.14<br/>(0.97 to 1.33) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.7%<br/>(59.3 to 81.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6% more<br/>(1.8 fewer to 20.2 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroids probably result in little or no difference to the return to normal hearing at 12 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific quality of life (total OM8‐30, lower score is more favourable)</p> <p>Follow‐up: 12 months (medium‐term)</p> <p>№ of participants: 304 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disease‐specific quality of life was ‐0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 higher<br/>(0.2 lower to 0.34 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroids probably result in little or no difference in disease‐specific quality of life at 12 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence/persistence of OME</p> <p>Follow‐up: range 6 months to 12 months (medium‐term)</p> <p>№ of participants: 352 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Two studies indicated that persistence of OME may be reduced in those who received steroids, but the size of the effect was very different, ranging from a RR of 0.18 (persistence of OME in placebo group of 67%, compared to 12% of those receiving steroids) to a RR of 0.86 (persistence of OME in placebo group of 93.8% compared to 80.5% of those receiving steroids). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroids may reduce the persistence of OME in the medium term, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event: systemic corticosteroid side effects</p> <p>Follow‐up ranged from 12 days to 12 months</p> <p>№ of participants: 264 (3 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Without reporting directly on the incidence of systemic corticosteroid side effects, 3 studies provided information from which it may be reasonable to assume none occurred. One reported an asthma attack as the only serious adverse event and reported an adjusted OR of 0.59 (95% CI 0.28 to 1.27) for having no adverse effects (adjusted for site and age group at recruitment; data pooled across all follow‐up time points of 1, 2, 3, 4 and 5 weeks) (<a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>). One study reported that none of the adverse events were classified as serious (<a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>), and one further study reported that no significant adverse effects were seen in any study participant (<a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>). Further information is provided in <a href="./full#CD015255-tbl-0002">Table 1</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the risk of systemic corticosteroid side effects with the use of oral steroids. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>OME:</b> otitis media with effusion; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for imprecision as the optimal information size (OIS) was not reached (&lt; 300 events) and the confidence interval crossed one decision threshold (RR 1.25). </p> <p><sup>2</sup>Downgraded one level for imprecision as the OIS was not reached (&lt; 400 participants). </p> <p><sup>3</sup>Downgraded two levels for imprecision as the OIS was not reached (&lt; 400 participants) and an estimate of the effect size was not possible, due to a narrative synthesis. </p> <p><sup>4</sup>Downgraded by one level for detection bias. </p> <p><sup>5</sup>Downgraded by two levels for imprecision as this was a narrative synthesis with zero reported events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015255-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Adverse event reporting: oral steroid</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event report</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Steroid type, dosage and duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Serious" or "severe" adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Only one serious adverse event was reported during the trial: one child in the placebo group had an asthma attack." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"One child reported fever and sore throat that was classified as a severe adverse event, but considered to have an unlikely association with treatment given. None of the adverse events were classified as serious." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Possible side‐effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 22/69; antibiotic + placebo: 17/66; RR 1.24 (95% CI 0.72 to 2.11) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tapering dose of oral dexamethasone for 13 days, starting at a max dose of 6 mg:</p> <p>0.15 mg/kg per day up to a maximum of 6 mg on days 1 and 2; 0.075 mg/kg per day (to a max of 3 mg/day) on days 3 and 4; 0.0375 mg/kg/day (to a max of 1.5 mg per day) on days 5, 6 and 7; 0.0375 mg/kg/day (to a max of 1.5 mg per day in children over 40 kg and 0.75 mg per day in children less than 40 kg) on days 9, 11 and 13 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant adverse effects were seen in any study participant."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone 1 mg per kg per day in 2 divided doses for a week followed by 0.5 mg per day for 1 week </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No adverse effect was reported from group C (oral steroid)."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of 6 mg betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No side effects of oral or intranasal steroids were reported in our patients"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted OR<sup>a</sup> 0.59 (95% CI 0.28 to 1.27) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 3/179; placebo: 1/170. RR 2.85 (95% CI 0.30 to 27.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 10/69; antibiotic + placebo: 6/66; RR 1.59 (95% CI 0.61 to 4.14) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 2/179; placebo: 0/170; Peto OR 7.07 (95% CI 0.44 to 113.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tired</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 1/179; placebo: 1/170; RR 0.95 (95% CI 0.06 to 15.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frustration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 0/179; placebo: 1/170; Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 1/69; antibiotic + placebo: 2/66; RR 0.48 (95% CI 0.04 to 5.15) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability and polyphagia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 1 mg/kg/day for the first 2 days in a divided dose, 0.75 mg/kg/day for the next 2 days and 5 to 10 mg/day as a single morning dose for the remaining 3 days. If partial clearing another week of prednisone 5 to 10 mg in a single morning dose on alternate days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Only one child treated with the prednisone/sulfa manifested symptoms of irritability and polyphagia; this was the only complication of therapy in the 40 children treated with corticosteroids." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleepwalking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 1/179; placebo: 0/170; Peto OR 7.03 (95% CI 0.14 to 354.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No symptoms of changes in behaviour and mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt;5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted OR<sup>a</sup> 0.76 (95% CI 0.49 to 1.19) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (95% CI 0.16 to 3.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 8/69; antibiotic + placebo: 4/66; RR 1.91 (95% CI 0.60 to 6.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.13 (95% CI 0.01 to 2.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.27 (95% CI 0.29 to 5.57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.5 to 1.0 mg/kg/dose twice a day for 7 days (plus antibiotic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No side effects were noted in patients treated with prednisone and/or TMP/SMZ (antibiotic) other than one patient with a self limited episode of vomiting. The relationship of the vomiting to the TMP/SMZ and prednisone was unclear." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 1/59; antibiotic + placebo: 3/61 RR 0.34 (95% CI 0.04 to 3.22) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 3/69; antibiotic + placebo: 2/66; RR 1.43 (95% CI 0.25 to 8.32) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 1/179; placebo: 0/170; Peto OR 7.03 (95% CI 0.14 to 354.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stomach pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 2/59; antibiotic + placebo: 2/61; RR 1.03 (95% CI 0.15 to 7.10) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 1/69; antibiotic + placebo: 2/66; RR 0.48 (95% CI 0.04 to 5.15) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 2/179; placebo: 2/170; RR 0.95 (95% CI 0.14 to 6.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 4/59; antibiotic + placebo: 2/61; RR 2.07 (95% CI 0.39 to 10.87) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loose stools</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 2/59; antibiotic + placebo: 2/61; RR 1.03 (95% CI 0.15 to 7.10) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 4/69; antibiotic + placebo: 1/66; RR 3.83 (95% CI 0.44 to 33.35) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 0/59; antibiotic + placebo: 1/161; Peto OR 0.14 (95% CI 0.00 to 7.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 1/179; placebo: 1/170; RR 0.95 (95% CI 0.06 to 15.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No symptoms of nausea, vomiting or indigestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted OR<sup>a</sup> 0.67 (95% CI 0.4 to 1.11) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dermatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 1/59; antibiotic + placebo: 0/61; Peto OR 7.64 (95% CI 0.15 to 385.43) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 0/69; antibiotic + placebo: 1/66; Peto OR 0.13 (95% CI 0.00 to 6.52) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash, pox or scarlet fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.13 (95% CI 0.01 to 2.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flushed cheeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.03 (95% CI 0.14 to 354.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 4/69; antibiotic + placebo: 2/66; RR 1.91 (95% CI 0.36 to 10.10) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phlegmy cough, cold, sneezing, temperature, nosebleed, conjunctivitis, itchy eyes, or generally unwell </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.32 (95% CI 0.70 to 15.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parotitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain on touch or earache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (95% CI 0.06 to 15.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parent states child not hearing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 0/179; placebo: 1/170. Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finger infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 0/179; placebo: 1/170. Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Knee pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 0/179; placebo: 1/170. Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Adjusted for site and child’s age group at recruitment (2 to 5 years and 6 to 8 years), data pooled across all follow‐up time points (1, 2, 3, 4 and 5 weeks). </p> <p>CI: confidence interval; OR: odds ratio; RR: risk ratio</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015255-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral steroids compared to no treatment for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Oral steroids compared to no treatment for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children aged 6 months to 12 years with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> oral steroids <br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without oral steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With oral steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hearing</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data were identified for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐specific quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data were identified for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence/persistence of OME (3 to 9 months ‐ medium‐term)</p> <p>№ of participants: 258 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/>(0.89 to 1.17) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.5%<br/>(65 to 85.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% more<br/>(8 fewer to 12.4 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that oral steroids may result in little or no difference in the persistence of OME in the medium term, when compared with no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event: systemic corticosteroid side effects</p> <p>Follow‐up: 1 month</p> <p>№ of participants: 40 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>One trial reported that none of 40 participants given oral prednisolone in a tapering course over 2 weeks reported adverse effects over 1 month of follow‐up (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>). Further information is available in <a href="./full#CD015255-tbl-0002">Table 1</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of a 2‐week tapering course of prednisolone on the risk of systemic corticosteroid side effects at 1 month of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for a risk of performance bias. </p> <p><sup>2</sup>Downgraded by one level for imprecision, as the optimal information size (OIS) was not reached (&lt; 300 events). </p> <p><sup>3</sup>Downgraded by two levels for a risk of performance and detection bias (arising from lack of blinding and brief follow‐up). </p> <p><sup>4</sup>Downgraded by two levels for very serious imprecision, due to a narratively reported outcome, with zero reported cases amongst a small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015255-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Topical (intranasal) steroids compared to placebo for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Topical (intranasal) steroids compared to placebo for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children aged 6 months to 12 years with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> topical (intranasal) steroids <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without topical steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With topical steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing ‐ hearing threshold; assumed ICC = 0.5</p> <p>Follow‐up: 2 months (short‐term)</p> <p>№ of participants: 78 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in hearing threshold (short‐term), ICC = 0.5, without nasal steroid was ‐7.6 dB </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 dB lower<br/>(6.05 lower to 5.45 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of nasal steroids on change in hearing threshold at 2 months, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific quality of life (total OM8‐30 score, lower score is more favourable)</p> <p>Follow‐up: 9 months (medium‐term)</p> <p>№ of participants: 82<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disease‐specific quality of life (medium‐term) without nasal steroid was 2.87 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.05 higher<br/>(0.36 lower to 0.46 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that nasal steroids result in little to no difference in disease‐specific quality of life at 9 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence/persistence of OME</p> <p>Follow‐up: up to 1 year (medium‐term)</p> <p>№ of participants: 206 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Two studies reported this outcome, but the results were conflicting. One study showed some benefit to intranasal steroids, whilst the other showed a potential increase in the number of children with persistent OME. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of nasal steroids on persistence of OME at up to 12 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event: systemic corticosteroid side effects</p> <p>Follow‐up: range 9 months to 2 years</p> <p>№ of participants: 157 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Without reporting directly on the incidence of systemic corticosteroid side effects, 2 studies provided information from which it may be reasonable to assume none occurred. One study reported that there were no serious adverse events and that growth rate was unaffected over 2 years (<a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>). A second study reported that there were no serious adverse events, suspected serious adverse reactions or related hospitalisations (<a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the risk of systemic corticosteroid side effects with nasal steroids over 2 years. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>ICC:</b> intracluster correlation coefficient; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for risk of bias, due to the potential for selection bias, detection bias and reporting bias. </p> <p><sup>2</sup>Downgraded by one level for imprecision, as the optimal information size (OIS) was not reached (&lt; 400 participants). </p> <p><sup>3</sup>Downgraded by one level due to the risk of attrition bias. </p> <p><sup>4</sup>Downgraded by one level for risk of bias, due to concerns over reporting bias and attrition bias. </p> <p><sup>5</sup>Downgraded by two levels for imprecision, as this was a narrative synthesis (therefore no estimate of effect could be provided) and the OIS was not reached (&lt; 300 events). </p> <p><sup>6</sup>Downgraded by two levels for very serious imprecision as this is a narrative synthesis, with zero events in either of two studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015255-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topical (intranasal) steroids compared to no treatment for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Topical (intranasal) steroids compared to no treatment for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children aged 6 months to 12 years with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> topical (intranasal) steroids<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without topical steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With topical steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing ‐ hearing threshold (air‐bone gap, very short‐term); assumed ICC = 0.5</p> <p>Follow‐up: 4 weeks</p> <p>№ of participants: 168 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean air‐bone gap without nasal steroid was 9.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.95 lower<br/>(3.85 lower to 0.05 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical (intranasal) steroids may make little or no difference to final hearing threshold at 4 weeks when compared to no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence/persistence of OME (short‐term); assumed ICC = 0.5</p> <p>Follow‐up: range 6 weeks to 8 weeks</p> <p>№ of participants: 134 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/>(0.57 to 0.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.5%<br/>(46.3 to 73.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8% fewer<br/>(34.9 fewer to 7.3 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of topical (intranasal) steroids on presence/persistence of OME at 6 to 8 weeks, when compared to no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event: systemic corticosteroid side effects</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported adverse events in sufficient detail to establish whether or not systemic corticosteroid side effects occurred. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>ICC:</b> intracluster correlation coefficient; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for risk of bias, due to concerns over performance and detection bias. </p> <p><sup>2</sup>Downgraded by one level for imprecision, as the optimal information size (OIS) was not reached (&lt; 400 participants). </p> <p><sup>3</sup>Downgraded by two levels for risk of bias, due to concerns over performance, detection and selection bias. </p> <p><sup>4</sup>Downgraded by one level for imprecision, as the OIS was not reached (&lt; 300 events) and the confidence interval crossed one decision threshold (RR 0.80). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015255-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015255-sec-0009"></div> <section id="CD015255-sec-0010"> <h3 class="title" id="CD015255-sec-0010">Description of the condition</h3> <p>Otitis media with effusion (OME) is a common condition in early childhood. The condition, also known as 'glue ear' or serous otitis media, is defined as "the presence of fluid in the middle ear without signs or symptoms of acute infection" (<a href="./references#CD015255-bbs2-0105" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154:S1-S41. [DOI: 10.1177/0194599815623467]">Rosenfeld 2016</a>). </p> <p>A key clinical feature of OME is hearing loss, due to decreased mobility of the tympanic membrane and consequent loss of sound conduction (<a href="./references#CD015255-bbs2-0105" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154:S1-S41. [DOI: 10.1177/0194599815623467]">Rosenfeld 2016</a>). Other symptoms that may be attributable to OME include balance (vestibular) problems and ear discomfort (<a href="./references#CD015255-bbs2-0105" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154:S1-S41. [DOI: 10.1177/0194599815623467]">Rosenfeld 2016</a>). When symptoms persist, they may lead to poor school performance and affect a child's daily activities, social interactions and emotions, possibly leading to a poorer quality of life for the child (<a href="./references#CD015255-bbs2-0103" title="RosenfeldRM , BhayaMH , BowerCM , BrookhouserPE , CasselbrantML , ChanKH , et al. Impact of tympanostomy tubes on child quality of life. Archives of Otolaryngology--Head &amp; Neck Surgery2000;126:585-92.">Rosenfeld 2000</a>). </p> <p>It is thought that up to 80% of children have had OME by the age of four years, but a decline in its prevalence is observed for children beyond six years of age (<a href="./references#CD015255-bbs2-0116" title="WilliamsonI . Otitis media with effusion in children. BMJ Clinical Evidence2011;2011:0502. [PMID: 21477396]">Williamson 2011</a>). Most episodes of OME in children resolve spontaneously within three months; however, approximately 35% of children will have more than one episode of OME and, furthermore, 5% to 10% of episodes will last for more than a year (<a href="./references#CD015255-bbs2-0105" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154:S1-S41. [DOI: 10.1177/0194599815623467]">Rosenfeld 2016</a>). Children with OME following an episode of untreated acute otitis media (AOM) have a 59% rate of resolution by one month, rising to 74% by three months, while children with newly diagnosed OME of unknown duration demonstrate a resolution rate of 28% by three months and up to 42% by six months (<a href="./references#CD015255-bbs2-0104" title="RosenfeldRM , Kay D. Natural history of untreated otitis media. Laryngoscope2003;113:1645-57. [DOI: 10.1097/00005537-200310000-00004]">Rosenfeld 2003</a>). The condition is more prevalent in children with Down syndrome or cleft palate (<a href="./references#CD015255-bbs2-0068" title="FlynnT , MöllerC , JönssonR , Lohmander A. The high prevalence of otitis media with effusion in children with cleft lip and palate as compared to children without clefts. International Journal of Pediatric Otorhinolaryngology2009;73:1441-6. [DOI: 10.3310/hta18600]">Flynn 2009</a>; <a href="./references#CD015255-bbs2-0088" title="MarisM , WojciechowskiM , Van de HeyningP , BoudewynsA . A cross-sectional analysis of otitis media with effusion in children with Down syndrome. European Journal of Pediatrics2014;173:1319-25. [DOI: 10.1007/s00431-014-2323-5]">Maris 2014</a>). Atopy has been considered a potential risk factor for OME in children (<a href="./references#CD015255-bbs2-0080" title="Kreiner-MøllerE , ChawesBLK , Caye-ThomasenP , BønnelykkeK , BisgaardH . Allergic rhinitis is associated with otitis media with effusion: a birth cohort study. Clinical and Experimental Allergy2012;42(11):1615-20. [DOI: 10.1111/j.1365-2222.2012.04038.x]">Kreiner‐Møller 2012</a>; <a href="./references#CD015255-bbs2-0089" title="MarsegliaGL , PagellaF , CaimmiD , CaimmiS , CastellazziAM , PoddigheD , et al. Increased risk of otitis media with effusion in allergic children presenting with adenoiditis. Otolaryngology – Head and Neck Surgery2008;138(5):572-5. [DOI: 10.1016/j.otohns.2008.01.020]">Marseglia 2008</a>; <a href="./references#CD015255-bbs2-0117" title="ZernottiME , PawankarR , AnsoteguiI , BadellinoH , CroceJS , HossnyE , et al. Otitis media with effusion and atopy: is there a causal relationship?World Allergy Organization Journal2017;10(1):37. [DOI: 10.1186/s40413-017-0168-x]">Zernotti 2017</a>). </p> <p>Diagnosis of OME is typically by clinical examination including (pneumatic) otoscopy and/or tympanometry in primary care. Following diagnosis, there will often be a period of active observation for at least three months. During the observation period, the care provider may offer a non‐surgical intervention such as hearing aids or autoinflation. The National Institute for Health and Care Excellence (NICE) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO‐HNS) do not currently recommend the use of antibiotics, antihistamines, decongestants or corticosteroids for OME as there is insufficient evidence to suggest they are effective treatments (<a href="./references#CD015255-bbs2-0095" title="National Institute for Health and Care Excellence. Otitis media with effusion in under 12s: surgery. Clinical guideline [CG60]. Published: 27 February 2008. https://www.nice.org.uk/guidance/cg60.">NICE 2008</a>; <a href="./references#CD015255-bbs2-0105" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154:S1-S41. [DOI: 10.1177/0194599815623467]">Rosenfeld 2016</a>). If OME has not resolved within the three‐month observation period, the child may be referred for further management/active intervention. This may include hearing aid provision or review by an ENT surgeon for consideration for myringotomy, ventilation tubes insertion and/or adenoidectomy. The choice of active intervention varies considerably. Earlier active intervention may be considered for children at increased risk of developmental difficulties (see <a href="./references#CD015255-bbs2-0105" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154:S1-S41. [DOI: 10.1177/0194599815623467]">Rosenfeld 2016</a> for a list of 'at‐risk' factors). </p> <p>This Cochrane Review focusses on topical and oral steroids as treatment for OME in children. This review forms part of a suite of five reviews of OME treatment, which will address those interventions identified in a prioritisation exercise as being most important and in need of up‐to‐date Cochrane reviews, namely ventilation tubes, adenoidectomy with or without ventilation tubes, autoinflation, antibiotics, and topical and oral steroids (<a href="./references#CD015255-bbs2-0064" title="CochraneENT . Otitis media with effusion: a project to prioritise Cochrane systematic reviews. https://ent.cochrane.org/otitis-media-effusion-ome-glue-ear 2020 (accessed 3 November 2021).">Cochrane ENT 2020</a>). </p> </section> <section id="CD015255-sec-0011"> <h3 class="title" id="CD015255-sec-0011">Description of the intervention</h3> <p>Steroids have been used with the intention of reducing the inflammatory cascade that causes Eustachian tube dysfunction and middle ear effusion (<a href="./references#CD015255-bbs2-0112" title="VannesteP , PageC . Otitis media with effusion in children: pathophysiology, diagnosis, and treatment. A review. Journal of Otology2019;14(2):33-9. [DOI: 10.1016/j.joto.2019.01.005]">Vanneste 2019</a>). They have been administered systemically as an oral preparation and topically as a nasal spray. Both oral and topical (intranasal) steroids are included in this review, at any dose, frequency and duration of administration. Both routes of administration are of interest, although their efficacy and mode of action may differ. In terms of safety, there is a potential for children to experience adverse effects associated with systemically administered steroids, such as osteoporosis and growth retardation, with suggestions that intranasal steroids may not lead to these abnormalities (<a href="./references#CD015255-bbs2-0094" title="MushtaqT , AhmedSF . The impact of corticosteroids on growth and bone health. Archives of Disease in Childhood2002;87:93-6. [DOI: 10.1136/adc.87.2.93]">Mushtaq 2002</a>). </p> </section> <section id="CD015255-sec-0012"> <h3 class="title" id="CD015255-sec-0012">How the intervention might work</h3> <p>Chronic inflammation in the middle ear produces inflammatory mediators, including arachidonic acid metabolites. Steroids may exert a beneficial effect on middle ear effusion by stabilising membrane phospholipid breakdown, thus preventing the formation of arachidonic acid and, in turn, inflammatory mediators (<a href="./references#CD015255-bbs2-0101" title="RosenfeldRM , MandelEM , BluestoneCD . Systemic steroids for otitis media with effusion in children. Archives of Otolaryngology--Head &amp; Neck Surgery1991;117(9):984-9. [DOI: 10.1001/archotol.1991.01870210056008]">Rosenfeld 1991</a>). In addition, steroids may have an effect on OME by shrinking peritubal lymphoid tissue, promoting secretion of Eustachian tube surfactant, and reducing the viscosity of middle ear fluid (<a href="./references#CD015255-bbs2-0101" title="RosenfeldRM , MandelEM , BluestoneCD . Systemic steroids for otitis media with effusion in children. Archives of Otolaryngology--Head &amp; Neck Surgery1991;117(9):984-9. [DOI: 10.1001/archotol.1991.01870210056008]">Rosenfeld 1991</a>). Whilst systemic steroids may have a direct effect on the middle ear, intranasal steroids are likely to exert their effect locally through reduction of nasal or adenoid tissue inflammation, which may in turn improve Eustachian tube function and promote resolution of OME. </p> </section> <section id="CD015255-sec-0013"> <h3 class="title" id="CD015255-sec-0013">Why it is important to do this review</h3> <p>A Cochrane Review assessing topical and oral steroids for hearing loss associated with OME was published in 2011 (<a href="./references#CD015255-bbs2-0120" title="SimpsonSA , LewisR , van derVoortJ , ButlerCC . Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. Cochrane Database of Systematic Reviews2011, Issue 5. Art. No: CD001935. [DOI: 10.1002/14651858.CD001935.pub3]">Simpson 2011</a>). This review included 12 studies (nine for oral steroids and three for topical intranasal steroids), none of which documented hearing loss associated with OME prior to randomisation. The authors concluded that <i>"while oral steroids, especially when used in combination with an oral antibiotic, lead to a quicker resolution of OME in the short term, there is no evidence of a longer‐term benefit and no evidence that they relieve symptoms of hearing loss"</i>. The authors also found no evidence of short‐ or long‐term benefit from the use of topical intranasal steroids either alone or in combination with an antibiotic. </p> <p>Since the Cochrane Review was published in 2011, the findings from a number of randomised controlled trials (RCTs) have been published, including those from the OSTRICH study (<a href="./references#CD015255-bbs2-0069" title="FrancisNA , Cannings-JohnR , Waldron C-A, Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [DOI: 0.1016/S0140-6736(18)31490-9]">Francis 2018</a>), a randomised study of the effects of a short course of oral steroids for hearing loss in 389 children with persistent OME, and from a second RCT that evaluated the effects of oral and intranasal steroids in 290 children with OME (<a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>). A prioritisation exercise undertaken in 2020 identified a review of topical and oral steroids as a top priority (<a href="./references#CD015255-bbs2-0064" title="CochraneENT . Otitis media with effusion: a project to prioritise Cochrane systematic reviews. https://ent.cochrane.org/otitis-media-effusion-ome-glue-ear 2020 (accessed 3 November 2021).">Cochrane ENT 2020</a>). It is therefore timely to update the evidence. </p> <p>This review has been produced as part of a suite of reviews, which also inform a NICE guideline on the management of OME in children (<a href="./references#CD015255-bbs2-0096" title="National Institute for Health and Care Excellence. Otitis media with effusion in under 12s. NICE guideline [NG233]. Published: 30 August 2023. https://www.nice.org.uk/guidance/ng233.">NICE 2023</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015255-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015255-sec-0014"></div> <p>To assess the effects (benefits and harms) of topical and oral steroids for otitis media with effusion (OME) in children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015255-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015255-sec-0015"></div> <section id="CD015255-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015255-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and quasi‐randomised trials (where trials were designed as RCTs, but the sequence generation for allocation of treatment used methods such as alternative allocation, birth dates and alphabetical order). We included studies that randomised by participant or by cluster. For cross‐over studies, we included data from the first phase of the study only (prior to cross‐over). </p> </section> <section id="CD015255-sec-0018"> <h4 class="title">Types of participants</h4> <p>Children aged 6 months to 12 years with unilateral or bilateral OME. If a study included children aged younger than 6 months or older than 12 years, we included the study if the majority of children fit our inclusion criteria or if the trialists presented outcome data by age group. We included all children regardless of any comorbidity such as Down syndrome or cleft palate. </p> <p>Clinical diagnosis of OME was confirmed by oto(micro)scopy or tympanometry, or both.</p> </section> <section id="CD015255-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD015255-sec-0020"> <h5 class="title">Intervention</h5> <p>Topical (intranasal) and oral steroids.</p> </section> <section id="CD015255-sec-0021"> <h5 class="title">Comparators</h5> <p>The comparators were placebo or no treatment. We were interested in the following comparisons: </p> <p> <ul id="CD015255-list-0001"> <li> <p>oral steroids versus placebo;</p> </li> <li> <p>oral steroids versus no oral treatment;</p> </li> <li> <p>topical (intranasal) steroids versus placebo;</p> </li> <li> <p>topical (intranasal) steroids versus no topical treatment.</p> </li> </ul> </p> <p>If study participants also received other treatments ‐ for example antibiotics, mucolytics or decongestants ‐ we included these studies if both arms received identical treatments. </p> </section> </section> <section id="CD015255-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>We analysed the following outcomes in the review, but we did not use them as a basis for including or excluding studies. We assessed all outcomes at very short term (&lt; 6 weeks), short term (≤ 3 months), medium term (&gt; 3 months to ≤ 1 year) and long term (&gt; 1 year). </p> <section id="CD015255-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD015255-list-0002"> <li> <p>Hearing, measured as:</p> <ul id="CD015255-list-0003"> <li> <p>proportion of children whose hearing has returned to normal, with normal hearing defined as 20 dB HL or less (assessed using age‐appropriate tests); </p> </li> <li> <p>hearing threshold.</p> </li> </ul> </li> </ul> </p> <p>We anticipated that study data for these outcomes may be derived from a variety of assessment methods. To avoid loss of important evidence, we extracted all such data for analysis. However, we gave consideration to the appropriateness of pooling different types of data in meta‐analysis. Our selection of primary outcomes was based principally upon clinical importance, but also permits applicability across a variety of age‐appropriate assessment methods, and considers the types of outcome data that were most likely to be available. Accordingly, we regarded the proportion of participants whose hearing returned to normal as the most important measure of hearing impact. We considered medium‐ and long‐term outcome data as the most clinically important. </p> <p> <ul id="CD015255-list-0004"> <li> <p>Disease‐specific quality of life measured using a validated instrument, for example:</p> <ul id="CD015255-list-0005"> <li> <p>OM8‐30 (<a href="./references#CD015255-bbs2-0074" title="HaggardMP , SmithSC , NichollsEE . Quality of life and child behaviour. In: RosenfeldRM , BluestoneCD , editors(s). Evidence-Based Otitis Media. 2nd edition. Hamilton, Ontario: BC Decker Inc, 2003:401-29. [https://researchonline.lshtm.ac.uk/id/eprint/15108]">Haggard 2003</a>); </p> </li> <li> <p>Otitis Media‐6 (<a href="./references#CD015255-bbs2-0102" title="RosenfeldRM , GoldsmithAJ , TetlusL , BalzanoA . Quality of life for children with otitis media. Archives of Otolaryngology--Head &amp; Neck Surgery1997;123:1049-54. [DOI: 10.1001/archotol.1997.01900100019002]">Rosenfeld 1997</a>). </p> </li> </ul> </li> <li> <p>Adverse events ‐ systemic corticosteroid side effects.</p> </li> </ul> </p> </section> <section id="CD015255-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD015255-list-0006"> <li> <p>Presence/persistence of OME.</p> </li> <li> <p>Adverse events ‐ local nasal side effects.</p> </li> <li> <p>Receptive language skills, measured using a validated scale, for example:</p> <ul id="CD015255-list-0007"> <li> <p>Peabody Picture Vocabulary Test ‐ Revised (<a href="./references#CD015255-bbs2-0065" title="DunnLM , DunnDM . Peabody Picture Vocabulary Test, Fourth Edition (PPVT™-4). Pearson Education, 2007.">Dunn 2007</a>); </p> </li> <li> <p>relevant domains of the Reynell Developmental Language Scales (<a href="./references#CD015255-bbs2-0100" title="ReynellJH . Reynell Development Language Scales Manual. 2nd edition. Windsor, UK: NFER-Nelson, 1985.">Reynell 1985</a>); </p> </li> <li> <p>relevant domains of the Preschool Language Scale (PLS) (<a href="./references#CD015255-bbs2-0118" title="ZimmermanIL , SteinerVG , PondRE . Preschool Language Scale-3. San Antonio, TX: The Psychological Corporation, 1992.">Zimmerman 1992</a>); </p> </li> <li> <p>relevant domains of the Sequenced Inventory of Communication (SCID) (<a href="./references#CD015255-bbs2-0075" title="HedrickDL , PratherEM , TobinAR . Sequenced Inventory of Communication Development. Seattle, WA: University of Washington Press, 1984.">Hedrick 1984</a>). </p> </li> </ul> </li> <li> <p>Speech development, or expressive language skills, measured using a validated scale, for example: </p> <ul id="CD015255-list-0008"> <li> <p>Schlichting test (<a href="./references#CD015255-bbs2-0107" title="SchlichtingJE , Lutje SpelbergHC . Schlichting Test for Language Comprehension; Instruction Manual. Bohn Stafleu van Loghum, 2010.">Schlichting 2010</a>); </p> </li> <li> <p>Lexi list (<a href="./references#CD015255-bbs2-0106" title="SchlichtingJEPT , Lutje SpelbergHC . Lexilijst Begrip: An instrument to investigate language comprehension in children aged 15-25 months in the context of early identification. Amsterdam: Pearson Assessment &amp; Information BV, 2007.">Schlichting 2007</a>); </p> </li> <li> <p>relevant domains of the Reynell Developmental Language Scales (<a href="./references#CD015255-bbs2-0100" title="ReynellJH . Reynell Development Language Scales Manual. 2nd edition. Windsor, UK: NFER-Nelson, 1985.">Reynell 1985</a>); </p> </li> <li> <p>relevant domains of the PLS (<a href="./references#CD015255-bbs2-0118" title="ZimmermanIL , SteinerVG , PondRE . Preschool Language Scale-3. San Antonio, TX: The Psychological Corporation, 1992.">Zimmerman 1992</a>); </p> </li> <li> <p>relevant domains of the SCID (<a href="./references#CD015255-bbs2-0075" title="HedrickDL , PratherEM , TobinAR . Sequenced Inventory of Communication Development. Seattle, WA: University of Washington Press, 1984.">Hedrick 1984</a>). </p> </li> </ul> </li> <li> <p>Cognitive development, measured using a validated scale, for example:</p> <ul id="CD015255-list-0009"> <li> <p>Griffiths Mental Development Scales (<a href="./references#CD015255-bbs2-0073" title="GriffithsR . The Griffiths Mental Development Scales from Birth to Two Years, Manual, the 1996 revision. Henley: Association for Research in Infant and Child Development, Test Agency, 1996.">Griffiths 1996</a>); </p> </li> <li> <p>McCarthy General Cognitive Index (<a href="./references#CD015255-bbs2-0091" title="McCarthyD . Manual for the McCarthy Scales of Children's Abilities. New York: Psychological Corp, 1972.">McCarthy 1972</a>); </p> </li> <li> <p>Bayley Scales of Infant and Toddler Development (<a href="./references#CD015255-bbs2-0062" title="BayleyN . Bayley Scales of Infant and Toddler Development. 3rd edition. San Antonio, TX: Harcourt Assessment, Inc, 2006.">Bayley 2006</a>). </p> </li> </ul> </li> <li> <p>Psychosocial outcomes, measured using a validated scale, for example:</p> <ul id="CD015255-list-0010"> <li> <p>the Social Skills Scale of the Social Skills Rating System (<a href="./references#CD015255-bbs2-0072" title="GreshamFM , ElliottSN . Social Skills Rating System. Circle Pines, MN: American Guidance Service, 1990.">Gresham 1990</a>); </p> </li> <li> <p>Child Behaviour Checklist (<a href="./references#CD015255-bbs2-0061" title="AchenbachTM . Child Behavior Checklist. In: KreutzerJS , DeLucaJ , CaplanB , editors(s). Encyclopedia of Clinical Neuropsychology. New York, NY: Springer, 2011. [DOI: 10.1007/978-0-387-79948-3_1529]">Achenbach 2011</a>); </p> </li> <li> <p>Strengths and Difficulties Questionnaire (<a href="./references#CD015255-bbs2-0071" title="GoodmanR . The Strengths and Difficulties Questionnaire: a research note. Journal of Child Psychology and Psychiatry1997;38:581-6. [DOI: 10.1111/j.1469-7610.1997.tb01545.x]">Goodman 1997</a>); </p> </li> <li> <p>Pediatric Symptom Checklist (<a href="./references#CD015255-bbs2-0079" title="JellinekMS , MurphyJM , RobinsonJ , FeinsA , LambS , FentonT . Pediatric Symptom Checklist: screening school-age children for psychosocial dysfunction. Journal of Pediatrics1988;112(2):201-9. [DOI: 10.1016/s0022-3476(88)80056-8]">Jellinek 1988</a>). </p> </li> </ul> </li> <li> <p>Listening skills, for example listening to stories and instructions effectively. Given that there are few validated scales to assess listening skills in children with OME, we included any methods used by trialists. </p> </li> <li> <p>Generic health‐related quality of life assessed using a validated instrument, for example: </p> <ul id="CD015255-list-0011"> <li> <p>EQ‐5D (<a href="./references#CD015255-bbs2-0098" title="RabinR , deCharroF . EQ-5D: a measure of health status from the EuroQol Group. Annals of Medicine2001;33(5):337-43. [DOI: 10.3109/07853890109002087]">Rabin 2001</a>); </p> </li> <li> <p>TNO AZL Children’s QoL (TACQOL) (<a href="./references#CD015255-bbs2-0114" title="VerripsGH , VogelsAG , Verloove-VanhorickSP , FekkesM , KoopmanHM , KamphuisRP , et al. Health-related quality of life measure for children - the TACQOL. Journal of Applied Therapeutics1998;1(4):357-60.">Verrips 1998</a>); </p> </li> <li> <p>TNO AZL Pre‐school children QoL (TAPQOL) (<a href="./references#CD015255-bbs2-0067" title="FekkesM , TheunissenNC , BrugmanE , VeenS , VerripsEGH , KoopmanHM , et al. Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1–5-year-old children. Quality of Life Research2000;9:961-72. [DOI: 10.1023/a:1008981603178]">Fekkes 2000</a>); </p> </li> <li> <p>TNO AZL Infant Quality of Life (TAIQOL) (<a href="./references#CD015255-bbs2-0111" title="TNO - Prevention and Health/LUMC. TAIQOL - Questionnaire for parents of children aged 1 - 5 years. Leiden, The Netherlands: Leiden University Medical Center, 1997.">TNO 1997</a>); </p> </li> <li> <p>Infant Toddler Quality of Life Questionnaire (ITQOL) (<a href="./references#CD015255-bbs2-0082" title="LandgrafJM . The Infant/Toddler Child Health Questionnaire: conceptual framework, logic content, and preliminary psychometric results. Boston: Health Act, 1994.">Landgraf 1994</a>); </p> </li> <li> <p>Child Health Questionnaire (CHQ) (<a href="./references#CD015255-bbs2-0083" title="LandgrafJL , AbetzL , WareJE . The CHQ User’s Manual. Boston: The Health Institute, New England Medical Center, 1996.">Landgraf 1996</a>). </p> </li> </ul> </li> <li> <p>Parental stress, measured using a validated scale, for example:</p> <ul id="CD015255-list-0012"> <li> <p>Parenting Stress Index (<a href="./references#CD015255-bbs2-0060" title="AbidinRR . Parenting Stress Index Professional Manual. 3rd edition. Odessa, FL: Psychological Assessment Resources, 1995.">Abidin 1995</a>). </p> </li> </ul> </li> <li> <p>Vestibular function:</p> <ul id="CD015255-list-0013"> <li> <p>balance;</p> </li> <li> <p>co‐ordination.</p> </li> </ul> </li> <li> <p>Number of doctor‐diagnosed acute otitis media episodes within a specified time frame.</p> </li> </ul> </p> <p>These outcomes were identified as the most important in two studies that aimed to develop a core outcome set for children with OME (<a href="./references#CD015255-bbs2-0063" title="BruceI , HarmanN , WilliamsonP , TierneyS , CalleryP , MohiuddinS , et al. The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. Health Technology Assessment2015;19(68):1-374. [DOI: 10.3310/hta19680]">Bruce 2015</a>; <a href="./references#CD015255-bbs2-0085" title="LiuPZ , Ismail-KochH , StephensonK , DonneAJ , FergieN , DerryJ , et al. A core outcome set for research on the management of otitis media with effusion in otherwise-healthy children. International Journal of Pediatric Otorhinolaryngology2020;134:110029. [DOI: 10.1016/j.ijporl.2020]">Liu 2019</a>). As this review forms part of a suite of reviews of interventions for OME, not all outcomes are relevant for all reviews. </p> </section> </section> </section> <section id="CD015255-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane ENT Information Specialist conducted systematic searches for randomised controlled trials and controlled clinical trials. There were no language, publication year or publication status restrictions. We contacted original authors for clarification and further data if trial reports were unclear and we arranged translations of papers where necessary. The date of the search was 20 January 2023. </p> <section id="CD015255-sec-0026"> <h4 class="title">Electronic searches</h4> <p>Cochrane ENT Information Specialist searched:</p> <p> <ul id="CD015255-list-0014"> <li> <p>the Cochrane ENT Register (searched via the Cochrane Register of Studies to 20 January 2023); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL 2023, Issue 1), searched via the Cochrane Register of Studies to 20 January 2023; </p> </li> <li> <p>Ovid MEDLINE(R) Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 20 January 2023); </p> </li> <li> <p>Ovid EMBASE (1974 to 23 January 2023);</p> </li> <li> <p>Web of Science, Web of Science (1945 to 20 January 2023);</p> </li> <li> <p>ClinicalTrials.gov, <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>: </p> <ul id="CD015255-list-0015"> <li> <p>searched via the Cochrane Register of Studies to 20 January 2023;</p> </li> <li> <p>searched via <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a> to 20 January 2023; </p> </li> </ul> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), <a href="https://apps.who.int/trialsearch/" target="_blank">https://apps.who.int/trialsearch/</a>: </p> <ul id="CD015255-list-0016"> <li> <p>searched via the Cochrane Register of Studies to 20 January 2023;</p> </li> <li> <p>searched via <a href="https://apps.who.int/trialsearch/" target="_blank">https://apps.who.int/trialsearch/</a> to 20 January 2023. </p> </li> </ul> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for CENTRAL. The search strategies were designed to identify all relevant studies for a suite of reviews on various interventions for otitis media with effusion. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the Technical Supplement to Chapter 4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> version 6.1) (<a href="./references#CD015255-bbs2-0084" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2020</a>). Search strategies for major databases including CENTRAL are provided in <a href="./appendices#CD015255-sec-0143">Appendix 1</a>. </p> </section> <section id="CD015255-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists of identified publications for additional trials and contacted trial authors where necessary. The Information Specialist also ran non‐systematic searches of Google Scholar to retrieve grey literature and other sources of potential trials. </p> <p>We did not perform a separate search for adverse effects. We considered adverse effects described in included studies only. </p> </section> </section> <section id="CD015255-sec-0028"> <h3 class="title" id="CD015255-sec-0028">Data collection and analysis</h3> <section id="CD015255-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The Cochrane ENT Information Specialist used Cochrane's Screen4Me workflow to help assess the search results. Screen4Me comprises three components: </p> <p> <ol id="CD015255-list-0017"> <li> <p>Known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as 'a RCT' or as 'not a RCT'. </p> </li> <li> <p>The machine learning classifier (RCT model) (<a href="./references#CD015255-bbs2-0115" title="WallaceBC , Noel-StorrAH , MarshallIJ , CohenAM , SmalheiserNR , ThomasJ . Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach. Journal of the American Medical Informatics Association2017;24(6):1165-8. [DOI: 10.1093/jamia/ocx053]">Wallace 2017</a>), available in the Cochrane Register of Studies (CRS‐Web), which assigns a probability of being a true RCT (from 0 to 100) to each citation. Citations that are assigned a probability score below the cut‐point at a recall of 99% we assumed to be non‐RCTs. For those that scored on or above the cut‐point we either manually dual screened these results or sent them to Cochrane Crowd for screening. </p> </li> <li> <p>Cochrane Crowd is Cochrane's citizen science platform where the Crowd help to identify and describe health evidence. For more information about Screen4Me and the evaluations that have been done, please go to the Screen4Me website on the Cochrane Information Specialist's <a href="https://community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal" target="_blank">portal</a> and see <a href="./references#CD015255-bbs2-0090" title="MarshallJ , Noel-StorrAH , KuiperJ , ThomasJ , WallaceBC . Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods2018;9(4):602-14.">Marshall 2018</a>, <a href="./references#CD015255-bbs2-0092" title="Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. In: Global Evidence Summit; 2017 Sep 13-17; Cape Town, South Africa. 2017.">McDonald 2017</a>, <a href="./references#CD015255-bbs2-0097" title="Noel-StorrAH . Cochrane Crowd: new ways of working together to produce health evidence. In: Evidence Live; 2018 Jun 18-20; Oxford, UK. 2018.">Noel‐Storr 2018</a> and <a href="./references#CD015255-bbs2-0109" title="ThomasJ , Noel-StorrAH , MarshallI , WallaceB , McDonaldS , MavergamesC , et al, Living Systematic Review Network. Living systematic reviews 2: combining human and machine effort. Journal of Clinical Epidemiology2017;91:31-7.">Thomas 2017</a>. </p> </li> </ol> </p> <p>At least two review authors (KG, CM) independently screened titles and abstracts retrieved by the search to identify potentially relevant studies. Two review authors (KG, CM, SM) then independently evaluated the full text of each potentially relevant study to determine whether it met the inclusion/exclusion criteria for this review. Any differences were resolved by discussion and consensus, with the involvement of a third author (KW) where necessary. </p> </section> <section id="CD015255-sec-0030"> <h4 class="title">Screening eligible studies for trustworthiness</h4> <p>Two review authors (RC, KG, BT‐G, CM, MR, KW) screened all studies meeting our inclusion criteria for trustworthiness using a screening tool developed by Cochrane Pregnancy and Childbirth. This tool includes specified criteria to identify studies that are considered sufficiently trustworthy to be included in the review (see <a href="#CD015255-fig-0001">Figure 1</a> and <a href="./appendices#CD015255-sec-0144">Appendix 2</a>). For any studies that were assessed as being potentially 'high risk', we attempted to contact the study authors to obtain further information or address any concerns. In the protocol for this review, we stated that if we were unable to contact the authors, or there was persisting uncertainty about the study, then it would not be included in the review, and that we would perform a sensitivity analysis to assess the effect on our findings of including/excluding studies. </p> <div class="figure" id="CD015255-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool" data-id="CD015255-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool</p> </div> </div> </div> <p>However, we only identified six studies without any concerns regarding trustworthiness (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). We did identify a further five studies where we were unable to fully assess the baseline characteristics of participants (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>) or the numbers randomised to each group (<a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>), but otherwise had no concerns over trustworthiness. </p> <p>The remaining studies all had at least one concern with trustworthiness when using the tool. This included the following: </p> <p> <ul id="CD015255-list-0018"> <li> <p>Limited baseline characteristics, so that we were unable to assess the groups for similarity (and an additional concern ‐ see below) (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>). </p> </li> <li> <p>Concerns over baseline data (<a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>, where there was a numeric difference of two between groups for all characteristics). </p> </li> <li> <p>No trial registration, for studies published since 2010 (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>) or retrospective registration (<a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>). </p> </li> <li> <p>Full follow‐up, without adequate explanation (<a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>). </p> </li> <li> <p>Equal numbers allocated to each group without mention of blocked randomisation (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>). </p> </li> </ul> </p> <p>We were unsure whether this high level of studies with concerns reflected a genuine problem with the data from these studies, or whether the assessment tool was perhaps too sensitive. We note that this tool, and others used for the same purpose, has not yet been validated. </p> <p>Consequently, we decided to include all studies in the main analyses of this review, but we did investigate the effect of excluding studies with concerns over trustworthiness on the overall results (see <a href="#CD015255-sec-0042">Sensitivity analysis</a>). </p> </section> <section id="CD015255-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RC, KG, BT‐G, CM, MR, KW) independently extracted outcome data from each study using a standardised data collection form. Where a study had more than one publication, we retrieved all publications to ensure complete extraction of data. Any discrepancies in the data extracted by the two authors were checked against the original reports, and differences were resolved through discussion and consensus, with recourse to a third author where necessary. If required, we contacted the study authors for clarification. We included key characteristics of the studies, such as the study design, setting, sample size, population and the methods for defining or collecting outcome data in the studies. </p> <p>We extracted data on study findings according to treatment assignment, irrespective of whether study participants complied with treatment or received the treatment to which they were randomised. </p> <p>In addition to extracting pre‐specified information about study characteristics and aspects of methodology relevant to risk of bias, we extracted the following summary statistics for each trial and outcome: </p> <p> <ul id="CD015255-list-0019"> <li> <p>For continuous data: the mean values, standard deviation and number of patients for each treatment group at the different time points for outcome measurement. Where endpoint data were not available, we extracted the values for change‐from‐baseline data instead. If values for the individual treatment groups were not reported, where possible we extracted summary statistics (e.g. mean difference) from the studies. </p> </li> <li> <p>For binary data: we extracted information on the number of participants experiencing an event, and the number of participants assessed at that time point. If values for the individual treatment groups were not reported, where possible we extracted summary statistics (e.g. risk ratio) from the studies. </p> </li> <li> <p>For ordinal scale data: we did not identify data analysed using ordinal scales for this review. </p> </li> </ul> </p> <p>We pre‐specified time points of interest for the outcomes in this review. Where studies reported data at multiple time points, we took the longest available follow‐up point within each of the specific time frames. </p> </section> <section id="CD015255-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (RC, KG, BT‐G, CM, MR, KW) undertook assessment of the risk of bias of the included studies independently, with the following taken into consideration, as guided by <a href="./references#CD015255-bbs2-0076" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>: </p> <p> <ul id="CD015255-list-0020"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>We used the Cochrane risk of bias tool in RevMan 5.3 (<a href="./references#CD015255-bbs2-0099" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>), which involves describing each of these domains as reported in the study and then assigning a judgement about the adequacy of each entry: 'low', 'high' or 'unclear' risk of bias. </p> </section> <section id="CD015255-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised dichotomous data, such as presence of OME, as a risk ratio (RR) and 95% confidence interval (CI) and continuous data as a mean difference (MD) and 95% CI. For the outcomes presented in the summary of findings tables, we have provided both the relative and absolute measures of effect. </p> </section> <section id="CD015255-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>For this review we anticipated that the unit of analysis would be the child. However, some studies reported findings by ear and therefore we have used both the child and ear as the unit of analysis. </p> <p>All studies randomised participants to antibiotics or no treatment/placebo at the level of the child, as this is an intervention that affects both ears. Some studies in this review included children with bilateral OME, either exclusively (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>), or as a proportion of included participants (<a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>). This gave rise to a number of issues regarding the unit of analysis, as some studies reported outcomes (particularly the persistence of OME) for each ear. </p> <p>We considered that outcomes for ears within the same individual were likely to be correlated, for example if a child had resolution of OME in one ear they may be more likely to experience resolution in the contralateral ear. There is no complete independence between ears of the same individual. Standard meta‐analysis techniques assume that all data are independent. Therefore, inclusion of the raw data (for the number of ears) is likely to overestimate the precision of any effect and result in an excessively narrow confidence interval. </p> <p>To account for this correlation, we used suggested methods in <a href="./references#CD015255-bbs2-0076" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>, which are more commonly employed in the analysis of cluster‐randomised trials. We treated individuals who contributed two ears to the analysis (all of those with bilateral disease) as a 'cluster' of two data points. We then attempted to account for the correlation in these clusters, by assuming a certain correlation between ears of the same individual. We could not identify a figure for this correlation in the published literature, so we used an estimated correlation of 0.50 in the main analysis, but conducted sensitivity analyses using correlations of 0 and 1, to test the limits of this assumption. We then reduced the effective size of the trials by the 'design effect', which accounts for correlation between ears and the average cluster size (which would be 2 for trials where all children had bilateral disease, and less than 2 if trials included a mixture of children with bilateral and unilateral disease). </p> <p>If we had identified cluster‐randomised trials, we would have assumed that the data from participants was no longer independent and adjusted our analyses accordingly, using the design effect approach as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015255-bbs2-0077" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>)<i>.</i> If we had identified cross‐over RCTs then we would have included data from the first phase of the trial only. However, this was not necessary for the review. We did identify one multi‐arm trial in this review (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>). However, the interventions of interest were applicable to different comparisons in this review and thus pooling data from different arms was not required. </p> </section> <section id="CD015255-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study authors by email where data on an outcome of interest to the review were not reported but the methods described in the paper suggest that the outcome was assessed. We did the same if not all data required for meta‐analysis were reported. </p> </section> <section id="CD015255-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by examining the included studies for potential differences in the types of participants recruited, interventions or controls used, and the outcomes measured. We assessed statistical heterogeneity by considering both the I² statistic, which calculates the percentage of variability that is due to heterogeneity rather than chance, with values over 50% suggesting substantial heterogeneity, and the P value from the Chi² test (<a href="./references#CD015255-bbs2-0077" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD015255-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias as within‐study outcome reporting bias and between‐study publication bias. </p> <section id="CD015255-sec-0038"> <h5 class="title">Outcome reporting bias (within‐study reporting bias)</h5> <p>We assessed within‐study reporting bias by comparing the outcomes reported in the published report against the study protocol or trial registry, when this could be obtained. If the protocol or trial registry entry was not available, we compared the outcomes reported to those listed in the methods section of the published report. If results were mentioned but not reported in a way that allowed analysis (e.g. the report only mentions whether the results were statistically significant or not), we sought further information from the study authors. If no further information could be found, we noted this as being a 'high' risk of bias. If there was insufficient information to judge the risk of bias we noted this as an 'unclear' risk of bias (<a href="./references#CD015255-bbs2-0076" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </section> <section id="CD015255-sec-0039"> <h5 class="title">Publication bias (between‐study reporting bias)</h5> <p>We planned to produce a funnel plot to explore possible publication biases if we were able to pool 10 or more studies in a single analysis. However, we did not include sufficient studies in any meta‐analysis to warrant this. </p> </section> </section> <section id="CD015255-sec-0040"> <h4 class="title">Data synthesis</h4> <p>Where two or more studies reported the same outcome we performed a meta‐analysis using Review Manager 5 (<a href="./references#CD015255-bbs2-0099" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We report pooled effect measures for dichotomous outcomes as a risk ratio (RR) using the Mantel‐Haenszel methods. For continuous outcomes measured we report a mean difference (MD). We used a random‐effects model. </p> <p>Where it was not possible to pool the findings from studies in a meta‐analysis, we present the results of each study and provide a narrative synthesis of findings. </p> </section> <section id="CD015255-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses if sufficient data were available in trial reports: </p> <p> <ul id="CD015255-list-0021"> <li> <p>children with mild hearing loss versus moderate or worse;</p> </li> <li> <p>children with allergy versus those without (using the trialists own definition);</p> </li> <li> <p>children aged up to four years versus children aged four years and over;</p> </li> <li> <p>children with previous ventilation tubes versus those without ventilation tubes;</p> </li> <li> <p>children with cleft palate versus children without;</p> </li> <li> <p>children with Down syndrome versus children without.</p> </li> </ul> </p> <p>However, we did not find any data suitable for conducting most of these subgroup analyses. No studies provided subgroup data for children with different features (for example, for those with mild hearing loss, compared to those with moderate or worse hearing loss). Many of the studies did not provide sufficient background information (for example, on hearing level) for us to conduct subgroup analysis at the level of the individual study. Where data were provided, studies often recruited a mixed population that encompassed all subgroups (for example, most studies recruited children aged 2 to 10 years, not specifically children aged ≤ 6 years or older than 6 years). </p> </section> <section id="CD015255-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses to assess whether our findings were robust to decisions made regarding analyses and inclusion of studies: </p> <p> <ul id="CD015255-list-0022"> <li> <p>impact of model chosen: we compared the results using a random‐effects versus a fixed‐effect model; </p> </li> <li> <p>inclusion of studies at high risk of bias: we planned to compare the results including all studies versus excluding studies at overall high risk of bias, that is four or more of the seven domains of bias are rated as high risk (see <a href="#CD015255-sec-0032">Assessment of risk of bias in included studies</a>); </p> </li> <li> <p>inclusion of studies considered at high probability of trustworthiness, as assessed by the Trustworthiness Screening Tool (<a href="#CD015255-fig-0001">Figure 1</a>). </p> </li> </ul> </p> </section> <section id="CD015255-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two independent authors (CM, KG) used the GRADE approach to rate the overall certainty of evidence using GRADEpro GDT (<a href="https://gradepro.org/" target="_blank">https://gradepro.org/</a>). The certainty of evidence reflects the extent to which we are confident that an estimate of effect is correct, and we applied this in the interpretation of results. There are four possible ratings: high, moderate, low and very low. A rating of high certainty of evidence implies that we are confident in our estimate of effect and that further research is very unlikely to change our confidence in the estimate of effect. A rating of very low certainty implies that any estimate of effect obtained is very uncertain. </p> <p>The GRADE approach rates evidence from RCTs that do not have serious limitations as high certainty. However, several factors can lead to the downgrading of the evidence to moderate, low or very low. The degree of downgrading is determined by the seriousness of these factors: </p> <p> <ul id="CD015255-list-0023"> <li> <p>study limitations (risk of bias);</p> </li> <li> <p>inconsistency;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>imprecision; and</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> <p>When assessing imprecision, we used a minimally important difference of a risk ratio (or odds ratio) of 0.8 or 1.25 for dichotomous outcomes. For most continuous data we considered a minimally important difference to be half of the standard deviation for the control/comparator group. The exception to this was hearing thresholds, where a difference of 10 dB HL was used as the minimally important difference. </p> <p>We include summary of findings tables, constructed according to the recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015255-bbs2-0077" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>), for the following comparisons: </p> <p> <ul id="CD015255-list-0024"> <li> <p>oral steroids versus placebo;</p> </li> <li> <p>oral steroids versus no oral treatment;</p> </li> <li> <p>topical (intranasal) steroids versus placebo;</p> </li> <li> <p>topical (intranasal) steroids versus no topical treatment.</p> </li> </ul> </p> <p>We included the following four outcomes in the summary of findings tables:</p> <p> <ul id="CD015255-list-0025"> <li> <p>hearing;</p> </li> <li> <p>disease‐specific quality of life;</p> </li> <li> <p>presence/persistence of OME;</p> </li> <li> <p>adverse events ‐ systemic corticosteroid side effects.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015255-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015255-sec-0044"></div> <section id="CD015255-sec-0045"> <h3 class="title">Description of studies</h3> <section id="CD015255-sec-0046"> <h4 class="title">Results of the search</h4> <p>The searches (September 2021 and January 2023) retrieved a total of 7441 records; this was reduced to 4157 after the removal of duplicates. The Cochrane ENT Information Specialist sent all 4157 records to the Screen4Me workflow. The Screen4Me workflow identified 84 records as having previously been assessed: 50 had been rejected as not RCTs and 34 had been assessed as possible RCTs. The remaining 4073 records were sent to the RCT classifier, which rejected an additional 1514 records as not RCTs (with 99% sensitivity) and 116 records as possible RCTs. The Cochrane Crowd assessed 2443 of the remaining references, rejecting 1313 as not RCTs and identifying 1130 as possible RCTs. Following this process, the Screen4Me workflow rejected 2877 records and identified 1280 possible RCTs for title and abstract screening (see <a href="#CD015255-tbl-0006">Table 2</a>). </p> <div class="table" id="CD015255-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RCTs identified through Cochrane Crowd and the RCT classifier</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Possible RCTs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rejected</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Known assessments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT classifier</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1514</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane Crowd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1313</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2877</p> </td> </tr> </tbody> </table> </div> <p>We excluded 76 additional duplicates. We screened the titles and abstracts of the remaining 1204 records. We discarded 886 records and retrieved 318 full‐text records. We subsequently discarded an additional 236 irrelevant records and removed an additional five duplicates. </p> <p>We excluded 30 studies (linked to 34 records) with reasons recorded in the review (see <a href="./references#CD015255-sec-0154" title="">Characteristics of excluded studies</a>). </p> <p>We included 26 studies (40 records) where results were available (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). </p> <p>We identified one ongoing study (<a href="./references#CD015255-bbs2-0059" title="NCT03491098. The efficacy of nasal steroids in treatment of otitis media with effusion: a comparative study. https://clinicaltrials.gov/show/nct03491098 (first received 24 March 2018). [CENTRAL: CN-01586095] ">NCT03491098</a>). See <a href="./references#CD015255-sec-0156" title="">Characteristics of ongoing studies</a> for further details. </p> <p>We identified two studies that are awaiting assessment because we did not have enough information to determine eligibility (<a href="./references#CD015255-bbs2-0057" title="KoayB , ComminsDJ , BatesS , MitchellB , MooreA , BatesG , et al. In search of a medical treatment for otitis media with effusion (OME): a randomised double-blind controlled trial (RCT). In: 7th International Congress of Pediatric Otorhinolaryngology. Helsinki, Finland, 7-10 June 1998. 1998:64. [ABSTRACT NUMBER: 289] [CENTRAL: CN-00292550] ">Koay 1998</a>; <a href="./references#CD015255-bbs2-0058" title="TawfikS , BelalA , SorourW . A comparative study of the different treatment modalities of otitis media with effusion in children. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO). Oxford, UK, 11-14 September 2002. 2002:151, Abstract No. P2.26. [CENTRAL: CN-00508402] ">Tawfik 2002</a>). See <a href="./references#CD015255-sec-0155" title="">Characteristics of studies awaiting classification</a> </p> <p>A flow chart of study retrieval and selection is provided in <a href="#CD015255-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD015255-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD015255-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD015255-sec-0047"> <h4 class="title">Included studies</h4> <p>Details of the studies included in this review are provided in <a href="./references#CD015255-sec-0153" title="">Characteristics of included studies</a> and summarised in <a href="#CD015255-tbl-0007">Table 3</a>. </p> <div class="table" id="CD015255-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concomitant treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 12 years with OME (n = 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone furoate 50 µg per nostril per day for 1 month</p> <p>or</p> <p>Oral prednisone (1 mg/kg/day) for 1 week, then 0.5 mg/kg/day for a further week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study arm assessed antibiotics and antihistamine nasal decongestants (not relevant for this review) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 12 years with bilateral OME (n = 168)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone furoate spray, 50 µg/puff, 2 puffs per nostril once daily for 1 month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in both groups also received amoxicillin and clavulanic acid (90 g/kg/day) for 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years with OME (n = 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal beclomethasone, 1 puff per nostril (dose not given) for 4 weeks. Twice daily for children aged 1 to 5 years, 3 times daily for children aged 6 to 10 years. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants also received amoxicillin 50 mg/kg/day for 1 week and decongestant (nasal saline spray and pseudoephedrine syrup) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 8 years with OME (n = 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone (dose and frequency not stated) for 3 weeks, then a tapering dose for a further 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with middle ear effusion for ≥ 6 weeks despite at least 2 courses of antibiotics (n = 68). Mean age 2.5 to 3 years (range 5 months to 12 years). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisone 0.5 to 1.0 mg/kg/dose twice daily for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trimethoprim‐sulfamethoxazole 5 mg/kg/dose twice daily for 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with unresolved OME by 2‐week follow‐up crossed over to the alternative regimen, and therefore some participants received both interventions. These data were not included in the review. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with at least 3 months of bilateral OME (n = 62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone furoate 50 µg/nostril twice daily for 8 weeks, then reduced to alternate day dosing for a further 16 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (nasal saline spray), administered with the same frequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants had adenoid hypertrophy, and had failed to respond to "previous medical therapy" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 3 to 15 years with at least 3 months of bilateral or unilateral OME (n = 63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone furoate 100 µg daily, 1 spray in each nostril once a day for 6 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 months to 12 years with unilateral or bilateral OME (n = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone 1 mg/kg/day for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received 2 weeks of amoxicillin‐clavulanic acid (2 groups also received antihistamine for 2 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data from the relevant arms have been pooled for analysis, to allow a comparison of those who received steroids to those who did not </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with unilateral or bilateral OME of at least 3 months duration (n = 142) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre hospital in Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of 6 mg betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received cefixime 8 mg/kg/day for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Longer follow‐up was reported, but only for a subset of participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 11 years with bilateral OME (n = 202)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre hospital in Saudi Arabia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seven days of oral prednisolone, 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with unilateral or bilateral OME (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre hospital in Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide intranasal spray, 200 µg/day for 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received ampicillin/sulbactam 25 mg/kg/day for 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with bilateral OME for at least 3 months (n = 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre tertiary hospital in Bangladesh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 100 µg per nostril per day for 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline spray, used with the same frequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study arm assessed montelukast (not relevant for this review)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 15 years with OME (n = 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from an ENT clinic in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone once daily for 14 days according to the following schedule: 1.5 mg/kg/day for 4 days; 0.75 mg/kg/day for 4 days; 5 mg or 10 mg (depending on the child’s weight) every other day for 6 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo syrup, administered in the same way</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received either 125 mg or 250 mg amoxicillin 3 times daily for 14 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 to 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some participants received a second course of steroids (if resolution had started but was not complete by 10 days </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 14 years with uni‐ or bilateral OME (n = 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial from a private ENT clinic in Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclomethasone 100 µg per nostril twice daily for one month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (mean age 3 to 4 years) with OME for at least 3 weeks (n = 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial from a paediatric department of a hospital in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral dexamethasone, tapering dose for 13 days (starting dose 0.15 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some children in this trial had a middle ear effusion persisting after an episode of AOM </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 9 years with uni‐ or bilateral middle ear effusion (n = 144)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial from a children's hospital in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg twice daily for 10 days, then once daily for a further 4 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 40 mg/kg/day in 3 divided doses for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged ≤ 2 years with OME for at least 8 weeks (n = 26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial from a hospital in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tapering dose of oral dexamethasone for 13 days, starting at a dose of 0.15 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 8 years with bilateral OME for at least 3 months (n = 380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre trial conducted at 20 sites across the UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7‐day course of oral soluble prednisolone (20 mg per day for children aged 2 to 5, 30 mg per day for those aged &gt; 5 years) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 3 to 8 years with OME for at least 2 months (n = 150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted in Israel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 day tapering dose of oral prednisolone, with initial dose of 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 50 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 7 months to 11 years with OME (n = 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted in Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone 1 mg/kg/day, given as a tapering dose over 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfadiazine (18.5 mg/kg/day) and trimethoprim (6 mg/kg/day) for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that all participants received myringotomy at the start of the trial and at any follow‐up visit where an effusion was detected </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 6 years with OME (n = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted in Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal mometasone, 1 puff per nostril daily for 1 month (dose not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 10 with OME (n = 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted in Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone 1 mg/kg/day for 7 days, then tapered over next 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 8 years with OME for at least 3 months (n = 200)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted from a specialist OME clinic in the UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone propionate nasal spray 50 µg per nostril twice daily for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some children in the trial also received autoinflation as an additional, background treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No efficacy data were useable from this study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years with OME for at least 3 weeks (n = 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two‐centre trial from private practices in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone, 1 mg/kg/day to start, with a tapering does over 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfisoxazole 50 mg/kg/day for 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some participants received additional prednisolone (5 to 10 mg on alternate days for 1 week). Unclear how many participants this applies to. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (mean 4.5 years) with uni‐ or bilateral OME (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal beclomethasone twice daily for 5 to 8 weeks (dose not given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that 2 studies are reported in the same publication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 11 years with bilateral OME (n = 217)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre trial from the UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal mometasone furoate 50 µg per nostril once daily for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> </div> <section id="CD015255-sec-0048"> <h5 class="title">Study design</h5> <p>Almost all the studies included in this review were parallel‐group RCTs. We identified two cross‐over RCTs (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>), however we only utilised data from the first phase of these studies, prior to cross‐over (see <a href="#CD015255-sec-0017">Types of studies</a>). </p> <p>Most studies included two groups of interest (either nasal steroids compared to placebo or no treatment, or oral steroids compared to placebo or no treatment). One study included a comparison of both oral steroid and intranasal steroid with watchful waiting, therefore was included in two comparisons of interest (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>). A number of other studies included additional groups that were not applicable to this review, such as antibiotics, montelukast and myringotomy (<a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>). </p> </section> <section id="CD015255-sec-0049"> <h5 class="title">Location</h5> <p>Studies were conducted all across the world. We identified six studies conducted in the USA (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>), and three each from the UK (<a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>) and Iran (<a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>). Two studies were from India (<a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>), and a further two from Turkey (<a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>). The remaining studies were conducted in Australia (<a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>), Bangladesh (<a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>), Denmark (<a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>), Egypt (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>), Finland (<a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>), Israel (<a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>), Nepal (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>), Saudi Arabia (<a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>), South Korea (<a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>) and Sweden (<a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>). </p> </section> <section id="CD015255-sec-0050"> <h5 class="title">Number of participants</h5> <p>The number of participants enrolled in each study varied considerably:</p> <p> <ul id="CD015255-list-0026"> <li> <p>25 to 50 participants: <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>. </p> </li> <li> <p>51 to 100 participants: <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>. </p> </li> <li> <p>101 to 150 participants: <a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>. </p> </li> <li> <p>151 to 250 participants: <a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>. </p> </li> </ul> </p> <p>The largest study was the <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> study, which recruited 380 participants. </p> </section> <section id="CD015255-sec-0051"> <h5 class="title">Duration of follow‐up</h5> <p>Again, the duration of follow‐up and timing of outcome assessment was very varied. The shortest studies included between seven days and five weeks of follow‐up (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>). A number of studies conducted follow‐up at between six weeks and three months (<a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>). </p> <p>Only a small number of studies carried out follow‐up for longer than three months. This included six‐month follow‐up for <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>, <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a> and <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>, and nine‐month follow‐up for <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a> and <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>. The <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> study assessed final follow‐up at 12 months. One study conducted follow‐up at two years, but no outcome data were reported on the outcomes of interest to this review (<a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>). </p> </section> <section id="CD015255-sec-0052"> <h5 class="title">Participants</h5> <p>All studies included a majority of participants with our target age range of between 6 months and 12 years old. A few studies included some children who were slightly older or younger than our target population: </p> <p> <ul id="CD015255-list-0027"> <li> <p><a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a> (from 5 months of age to 12 years, mean age around 3 years). </p> </li> <li> <p><a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a> (from 3 to 15 years, mean age 6 to 7 years). </p> </li> <li> <p><a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a> (from 2 to 15 years, mean age 5 to 6 years). </p> </li> <li> <p><a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a> (from 4 to 14 years, mean age 6.5 years). </p> </li> <li> <p><a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a> (from 2 to 14 years). </p> </li> </ul> </p> <p>The duration of OME was not stated for the majority of studies, although some studies did require a specific duration of symptoms prior to enrolment ‐ predominantly either three months (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>) or six to eight weeks (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>). </p> <p>Most studies appeared to recruit children with either bilateral or unilateral disease. A few specifically enrolled children with bilateral disease (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). </p> <p>Little information was provided regarding previous treatment, although four studies specifically recruited children who had no response to prior treatment, including at least two courses of antibiotics (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>) or other 'medical treatment' (not described further, <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>). </p> </section> <section id="CD015255-sec-0053"> <h5 class="title">Intervention and comparator</h5> <section id="CD015255-sec-0054"> <h6 class="title">Oral steroids versus placebo</h6> <p>Eleven studies assessed this comparison (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>). The majority used treatment with oral prednisolone at a dose of between 0.5 mg/kg and 1.5 mg/kg per day, for between 6 and 14 days (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>). Two studies used dexamethasone instead of prednisolone for 13 days of treatment (<a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>). Many studies used a regime that included a tapering dose towards the end of the treatment period. One study used a single dose of 6 mg oral betamethasone (<a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>). </p> <p>Six studies included background treatment of antibiotics for all participants in the study ‐ those receiving steroids and those receiving placebo (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>). The overall effect estimated in these studies is still relevant for a comparison of steroids versus placebo. However, it should be borne in mind that, if antibiotics were particularly effective at treating OME, any additional effect of steroids may not be easily detected. </p> </section> <section id="CD015255-sec-0055"> <h6 class="title">Oral steroids versus no treatment</h6> <p>Three studies provided data for this comparison (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>). All used treatment with oral prednisolone, for between 7 and 14 days. One study used a tapering dose regime (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>). </p> <p>Again, one study in this comparison also provided all participants with a course of antibiotics, which may modify the effect estimates seen (<a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>). </p> </section> <section id="CD015255-sec-0056"> <h6 class="title">Topical (intranasal) steroids versus placebo</h6> <p>Six studies assessed this comparison (<a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). They used different preparations of intranasal steroids, including beclomethasone (<a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>), fluticasone (<a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>) and mometasone (<a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). The duration of treatment also varied from a minimum of two weeks (<a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>) up to three months (<a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). The participants in these studies did not receive additional, concomitant medication as part of the study protocol. </p> </section> <section id="CD015255-sec-0057"> <h6 class="title">Topical (intranasal) steroid versus no treatment</h6> <p>Seven studies assessed this comparison, including one three‐armed trial, which also provided data for the comparison of oral steroids and no treatment (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>). Most studies used mometasone (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>); the remaining two studies assessed beclomethasone (<a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>). The duration of treatment was one month for most studies (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>), six weeks for two studies (<a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>), and eight weeks for the final study (<a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>). </p> <p>Three studies also provided all participants with concomitant treatment of antibiotics for between one and eight weeks (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>). </p> </section> </section> <section id="CD015255-sec-0058"> <h5 class="title">Outcomes</h5> <section id="CD015255-sec-0059"> <h6 class="title">Hearing</h6> <p>Hearing was measured rather inconsistently across the studies, which often precluded meta‐analysis. Very few studies reported our preferred outcome measure of the proportion of children with a return to normal hearing. This was only described by the <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> study (the number of children with acceptable hearing) and <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>, where it was reported as the proportion of children with complete closure of the air‐bone gap. A number of studies did report on final hearing thresholds using either pure tone audiometry (<a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>), or the air‐bone gap (<a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>). </p> <p>We were unable to include data from several studies, due to insufficient information on the variance of the estimates (<a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>), no description of the number of participants in whom the outcome was measured (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>) or both (<a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>). One study only provided a narrative description of the results (<a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>). </p> </section> <section id="CD015255-sec-0060"> <h6 class="title">Disease‐specific health‐related quality of life</h6> <p>A single study measured this outcome. The <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> study used the OM8‐30 questionnaire to assess quality of life (<a href="./references#CD015255-bbs2-0110" title="TimmermanAA , MeestersCMG , AnteunisLJC , ChenaultMN , HaggardMP . Psychometric evaluation of the OM8-30 questionnaire in Dutch children with otitis media. European Archives of Oto-Rhino-Laryngology2008;265:1047-56.">Timmerman 2008</a>), as it relates to otitis media with effusion. Limited information regarding the scoring of this questionnaire is available. It appears that a type of standardised score is used, but the full range of potential scores and the minimally important difference is unclear. The authors indicate that lower (more negative) scores represent worse quality of life. </p> </section> <section id="CD015255-sec-0061"> <h6 class="title">Serious adverse events: systemic steroid side effects</h6> <p>Adverse effects were poorly and inconsistently reported across the studies. Many did not report on adverse effects at all, meaning that we were unsure whether these had been assessed but not reported, or whether no adverse effects were identified. Furthermore, the reporting of adverse effects meant that it was difficult to determine whether side effects were considered to be related to steroid use, or not. We therefore took an inclusive approach, and have included all adverse effects reported in the studies. These are presented in <a href="./full#CD015255-tbl-0002">Table 1</a> and <a href="#CD015255-tbl-0008">Table 4</a>. However, the variety of symptoms reported meant that no meta‐analysis was possible for this outcome. </p> <div class="table" id="CD015255-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse event reporting: intranasal steroid</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event report</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Steroid type, dosage and duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No serious adverse events"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone propionate aqueous nasal spray 50 µg per spray, 1 puff per nostril twice daily for 2 weeks (2 puffs per nostril twice daily for children over 35 kg), i.e. total daily dose 200 µg (or 400 µg) initially; then reduced to 1 puff per nostril (100 µg) once daily. “The children were asked to use this on a regular basis”. “Those who reported spray use on at least 3 days a week remained in the study” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over 2 years: "There were no serious adverse events in this study."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No serious adverse events, suspected serious adverse reactions or related hospitalisations occurred during the study." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Reported side‐effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: Nasal steroid: 45/96; placebo: 35/98; RR 1.31 (95% CI 0.93 to 1.84).</p> <p>At 3 months: nasal steroid: 29/86; placebo: 23/86; RR 1.26 (95% CI 0.80 to 1.99)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclomethasone dipropionate nasal spray administered twice in each nostril (100 µg per nostril) twice a day, for a total of 400 µg daily, for 1 month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Apart from that (the child’s response to the power of the nasal spray) complications in the use of the spray were not noticed, especially no signs of mycosis or atrophy of the nasal mucosa occurred." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No effect on growth"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone propionate (FP) aqueous nasal spray 50 µg per spray, 1 puff per nostril twice daily for 2 weeks (2 puffs per nostril twice daily for children over 35 kg), i.e. total daily dose 200 µg (or 400 µg) initially; then reduced to o1ne puff per nostril (100 µg) once daily. “The children were asked to use this on a regular basis”. “Those who reported spray use on at least 3 days a week remained in the study” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over 2 years: "The plots of growth rate (not presented) indicated a uniform increase in height over the time period, independent of treatment. The mixed model fitted indicated no significant difference in growth rates between those children receiving FP and those given placebo on either method of analysis." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nosebleed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril once a day for 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“One case (2.5%) from group B (nasal spray) reported blood tinged nasal discharge which was managed with nasal ointment and counselling regarding proper way of using nasal spray. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial treatment of 2 puffs of mometasone furoate nasal spray (50 µg/puff) in each nostril once a day (a total of 200 µg/day) for first 8 weeks, followed by 2 puffs in each nostril on alternate days for 16 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal saline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal steroid: 2/30; nasal saline: 3/32; RR 0.71 (95% CI 0.13 to 3.97; <a href="./references#CD015255-fig-0045" title="">Analysis 3.14</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone propionate aqueous nasal spray 50 µg per spray, 1 puff per nostril twice daily for 2 weeks (2 puffs per nostril twice daily for children over 35 kg), i.e. total daily dose 200 µg (or 400 µg) initially; then reduced to 1 puff per nostril (100 µg) once daily. “The children were asked to use this on a regular basis”. “Those who reported spray use on at least 3 days a week remained in the study” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Minor adverse events were recorded, but none was of sufficient severity to cause cessation of the treatment or withdrawal from the trial. The commonest was minor epistaxis which occurred in fewer than 10% of subjects." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: nasal steroid: 8/96; placebo: 7/98; RR 1.17 (95% CI 0.44 to 3.09)</p> <p>At 3 months: nasal steroid: 10/86; placebo: 6/86; RR 1.67 (95% CI 0.63 to 4.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stinging in the nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: nasal steroid: 9/96; placebo: 10/98; RR 0.92 (95% CI 0.39 to 2.16)</p> <p>At 3 months: nasal steroid: 9/86; placebo: 9/86; RR 1.00 (95% CI 0.42 to 2.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry throat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: nasal steroid: 13/96; placebo: 14/98; RR 0.95 (95% CI 0.47 to 1.91)</p> <p>At 3 months: nasal steroid: 10/86; placebo: 7/86; RR 1.43 (95% CI 0.57 to 3.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: nasal steroid: 23/96; placebo: 19/98; RR 1.24 (95% CI 0.72 to 2.12)</p> <p>At 3 months: nasal steroid: 19/86; placebo: 11/86; RR 1.73 (95% CI 0.88 to 3.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intolerance of administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclomethasone dipropionate nasal spray administered twice in each nostril (100 µg per nostril) twice a day, for a total of 400 µg daily, for 1 month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This produced a rather powerful spray, and often a mist would appear through the open mouth; thus the spray reached the rhinopharynx, but many children were scared initially and did not enter the study. In a few cases the treatment was discontinued for that reason." </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio</p> </div> </div> </section> <section id="CD015255-sec-0062"> <h6 class="title">Presence/persistence of OME</h6> <p>Assessment of the persistence of OME also varied across the studies, which may lead to some clinical heterogeneity in the effect sizes seen. We included data according to the authors' definition of 'persistent OME'. However, it should be noted that this was assessed as a type B tympanogram for some studies (including <a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>), and a "non‐type A" (i.e. type B or C) tympanogram for other studies (such as <a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>). Some studies included only those children with type B or C2 tympanograms as 'persistent OME' (<a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). </p> <p>In addition, there was variation in how persistent OME was assessed for children with bilateral disease: the majority of participants for most studies. Some studies assessed each ear separately (see <a href="#CD015255-sec-0034">Unit of analysis issues</a>), whilst others assessed persistence at the level of the child. For children in whom OME resolved in one ear (i.e. the disease changed from bilateral to unilateral), some studies classed these children as having persistent disease (<a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>), and others classed them as having resolved disease (<a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). A full description of methods used to classify children with bilateral disease was not available from many studies. </p> </section> <section id="CD015255-sec-0063"> <h6 class="title">Generic health‐related quality of life</h6> <p>Only two studies assessed this outcome. <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a> used the Glasgow Children's Benefit Inventory (<a href="./references#CD015255-bbs2-0081" title="KubbaH , SwanIRC , GatehouseS . The Glasgow Children's Benefit Inventory: a new instrument for assessing health-related benefit after an intervention. Annals of Otology, Rhinology and Laryngology2004;113(12):980-6.">Kubba 2004</a>). This is a 24‐item questionnaire that assesses the change in quality of life following an intervention. Scores range from ‐100 (maximum harm) to +100 (maximum benefit). The PedsQL™ (<a href="https://www.pedsql.org/" target="_blank">https://www.pedsql.org/</a>) was used in the <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> study. Scores for this instrument range from 0 to 100, with higher scores representing better quality of life. The minimally important difference has been proposed to be a change of 4.5 points (<a href="./references#CD015255-bbs2-0113" title="VarniJW , BurwinkleTM , SeidM , SkarrD . The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambulatory Pediatrics2003;3(6):329-41.">Varni 2003</a>). The Health Utilities Index 3 (<a href="./references#CD015255-bbs2-0066" title="FeenyD , FurlongW , TorranceGW , GoldsmithCH , ZhuZ , DePauw S et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care2002;40(2):113-28.">Feeny 2002</a>; <a href="./references#CD015255-bbs2-0078" title="HorsmanJ , FurlongW , FeenyD , TorranceG . The Health Utilities Index (HUI): concepts, measurement properties and applications. Health and Quality of Life Outcomes2003;1:54.">Horsman 2003</a>) was also used in the <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> study. This assesses health on a scale of 0 (dead) to 1 (perfect health). For their analysis, the study authors used a dichotomous scale, comparing the proportion of children with a score of perfect health between the two groups. </p> </section> <section id="CD015255-sec-0064"> <h6 class="title">Number of doctor‐diagnosed episodes of acute otitis media</h6> <p>Few studies assessed this outcome. <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a> reported on the proportion of children in whom a specific number of episodes of otitis media was exceeded. <a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>, <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> and <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a> considered the proportion of children who had an episode by two to four weeks of follow‐up. </p> </section> <section id="CD015255-sec-0065"> <h6 class="title">Other secondary outcomes</h6> <p>None of the included studies assessed developmental outcomes, including receptive and expressive language skills, cognitive development, psychosocial outcomes or listening skills. In addition, no studies considered parental stress or vestibular function. </p> </section> </section> </section> <section id="CD015255-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 30 studies (linked to 34 references) from this review. See <a href="./references#CD015255-sec-0154" title="">Characteristics of excluded studies</a> for further details. The main reasons for exclusion are listed below: </p> <p> <ul id="CD015255-list-0028"> <li> <p>We excluded 13 studies as they were not RCTs (<a href="./references#CD015255-bbs2-0027" title="Al-ZaidiHMH . Is mometasone effective in treating otitis media with effusion?Journal of Medical and Health Studies2023;4(1):47-55. ">Al‐Zaidi 2023</a>; <a href="./references#CD015255-bbs2-0029" title="Crawford-FaucherA . Intranasal corticosteroids do not cure otitis media with effusion. American Family Physician2010;82(8):992-4. [CENTRAL: CN-01016672] [EMBASE: 361807993]">Crawford‐Faucher 2010</a>; <a href="./references#CD015255-bbs2-0032" title="El-AnwarMW , NofalAA , KhazbakAO , SayedAE , HassanMR . The efficacy of nasal steroids in treatment of otitis media with effusion: a comparative study. International Archives of Otorhinolaryngology2015;19(4):298-301. [CENTRAL: CN-01332850] [EMBASE: 614397848] [PMID: 26491474]">El‐Anwar 2015</a>; <a href="./references#CD015255-bbs2-0035" title="GibsonPG , StuartJE , WlodarczykJ , OlsonLG , HensleyMJ . Nasal inflammation and chronic ear disease in Australian Aboriginal children. Journal of Paediatrics and Child Health1996;32(2):143-7. [CENTRAL: CN-00131589] [PMID: 8860389]">Gibson 1996</a>; <a href="./references#CD015255-bbs2-0040" title="IinoY , IshitoyaJ , IkedaM , ItoY , UsamiM , KawashiroN , et al. Factors on delayed recovery of otitis media with effusion in children--clinical and bacteriological study. Nihon Jibiinkoka Gakkai Kaiho1989;92(8):1183-91. [CENTRAL: CN-00063873] [PMID: 2685215]">Iino 1989</a>; <a href="./references#CD015255-bbs2-0044" title="ParadiseJ , CampbellT , DollaghanC , FeldmanH , BernardB , ColbornK , et al. Receptive vocabulary, cognition, and parent-rated behavior at age 3 years in relation to otitis media in the first 3 years of life. In: Abstract Book of the Association of Health Service Research. Vol. 14. 1997:350-1. [CENTRAL: CN-00452820] ">Paradise 1997</a>; <a href="./references#CD015255-bbs2-0045" title="ParleaE , GeorgescuM , CalarasuR . Tympanometry as a predictor factor in the evolution of otitis media with effusion. Journal of Medicine and Life2012;5(4):452-4. [CENTRAL: CN-00850240] [EMBASE: 369159817] [PMID: 23346249]">Parlea 2012</a>; <a href="./references#CD015255-bbs2-0046" title="PersicoM , PodoshinL , FradisM , FradisM . Otitis media with effusion: a steroid and antibiotic therapeutic trial before surgery. Annals of Otology, Rhinology, and Laryngology1978;87:191-5. ">Persico 1978</a>; <a href="./references#CD015255-bbs2-0048" title="SalmenMM , SalehEM , AbdEMM . The efficacy of nasal steroids in treatment of otitis media with effusion: a comparative study. Egyptian Journal of Neck Surgery and Otorhinolaryngology2021;7(1):20-7. ">Salmen 2021</a>; <a href="./references#CD015255-bbs2-0049" title="SchwartzRH , SchwartzDM , GrundfastKM . Intranasal beclomethasone in the treatment of middle ear effusion: a pilot study. Annals of Allergy1980;45(5):284-7. [PMID: 7436055]">Schwartz 1980a</a>; <a href="./references#CD015255-bbs2-0051" title="ShubichI . Otitis media with effusion and allergy control in children: a prospective study. In: Sixth International Symposium on Otitis Media; 1996; Fort Lauderdale (FL). 1996:173-4. [CENTRAL: CN-00452904] ">Shubich 1996</a>; <a href="./references#CD015255-bbs2-0052" title="StenstromR , PlessIB , BernardP . Hearing thresholds and tympanic membrane sequelae in children managed medically or surgically for otitis media with effusion. Archives of Pediatrics &amp; Adolescent Medicine2005;159(12):1151-6. [CENTRAL: CN-00532329] [PMID: 16330739]">Stenstrom 2005</a>; <a href="./references#CD015255-bbs2-0056" title="ZocconiE . Antibiotics and oral steroids in the treatment of otitis media with effusion. Pediatria Medica e Chirurgica1994;16(3):273-5. ">Zocconi 1994</a>). </p> </li> <li> <p>Four studies were commentaries and did not report results of a trial (<a href="./references#CD015255-bbs2-0031" title="DamoiseauxRA , RoversMM . Topical intranasal corticosteroids for otitis media with effusion in primary care. BMJ (Clinical Research Ed.)2010;340(7737):b5380. [EMBASE: 358169045] [PMID: 20056694]">Damoiseaux 2010</a>; <a href="./references#CD015255-bbs2-0039" title="HughesA , KhongT . Do oral steroids improve hearing outcomes in children with otitis media with effusion?Drug and Therapeutics Bulletin2019;57(11):166-7. [CENTRAL: CN-02081693] [EMBASE: 629508876] [PMID: 31558551]">Hughes 2019</a>; <a href="./references#CD015255-bbs2-0041" title="IsaacsD . Oral steroids for persistent otitis media with effusion. Journal of Paediatrics and Child Health2018;54(12):1399-400. [EMBASE: 625343699]">Isaacs 2018</a>; <a href="./references#CD015255-bbs2-0043" title="MayorS . Oral steroids fail to prevent hearing loss in children with otitis media with effusion, shows trial. BMJ2018;362:k3576. [CENTRAL: CN-01920979] [EMBASE: 623540485]">Mayor 2018</a>). </p> </li> <li> <p>Six studies included an irrelevant intervention, and did not assess the effect of topical or oral steroids, although some were included in other reviews in this suite (<a href="./references#CD015255-bbs2-0028" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015255-bbs2-0030" title="DalyK , GiebinkGS , BataldenPB , AndersonRS , LeCT , LindgrenB , et al. Resolution of otitis media with effusion with the use of a stepped treatment regimen of trimethoprim-sulfamethoxazole and prednisone. Pediatric Infectious Disease Journal1991;10(7):500-6. [CENTRAL: CN-00077629] [PMID: 1876465]DalyK , GiebinkGS , LindgrenB , AndersonRS . Controlled clinical trial for prevention of chronic otitis media with effusion. In: Proceedings of the 4th International Symposium on Recent Advances in Otitis Media; 1987 Jun 1-4; Toronto (ON). 1987:247-50. [CENTRAL: CN-00452502] ">Daly 1991</a>; <a href="./references#CD015255-bbs2-0033" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00187118] [EMBASE: 27225833]">Endo 1997</a>; <a href="./references#CD015255-bbs2-0042" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetriG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015255-bbs2-0047" title="RohailA , GillZI , ButtMR . A comparison of medical treatment versus surgical treatment for the management of otitis media with effusion. Annals of King Edward Medical College2006;12(1):64-7. [CENTRAL: CN-00597368] ">Rohail 2006</a>; <a href="./references#CD015255-bbs2-0054" title="VelepicM , StarcevicR , BonifacicM , TicacR , KujundzicM , UdovicDS , et al. The clinical status of the eardrum: an inclusion criterion for the treatment of chronic secretory otitis media in children. International Journal of Pediatric Otorhinolaryngology2011;75(5):686-90. [CENTRAL: CN-00784332] [EMBASE: 51315541] [PMID: 21397957]">Velepic 2011</a>). </p> </li> <li> <p>Six studies enrolled participants who did not fit our inclusion criteria, including:</p> <ul id="CD015255-list-0029"> <li> <p>children with recurrent acute otitis media (<a href="./references#CD015255-bbs2-0034" title="FerraraS , SammartanoD , FerraraP . Long-term management of recurrent otitis media with effusion in children. In: XVIII IFOS World Congress; 2005 Jun 25-30; Rome (Italy). 2005. [CENTRAL: CN-00526409] ">Ferrara 2005</a>; <a href="./references#CD015255-bbs2-0053" title="TracyJM , DemainJG , HoffmanK , GoetzDW . Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Annals of Allergy, Asthma &amp; Immunology1995;74:59. [CENTRAL: CN-00285148] TracyJM , DemainJG , HoffmanKM , GoetzDW . Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Annals of Allergy, Asthma &amp; Immunology1998;80(2):198-206. [CENTRAL: CN-00148310] [PMID: 9494455]">Tracy 1995</a>); </p> </li> <li> <p>children with an effusion immediately following an episode of acute otitis media (<a href="./references#CD015255-bbs2-0036" title="GiebinkGC , BataldenPB , LeCT , RussJN , KnoxJK , AndersonRS , et al. Randomized controlled trial comparing trimethoprim-sulfamethoxazole, prednisone, ibuprofen, and no treatment in chronic otitis media with effusion. Recent Advances Otitis Media: Proceedings of the Fourth International Symposium on Recent Advances in Otitis Media; 1988 Jun 1-4; Toronto (Canada)1988:240-4. [CENTRAL: CN-00452593] GiebinkGS , BataldenPB , LeCT , LassmanFM , BuranDJ , SeltzAE . A controlled trial comparing three treatments for chronic otitis media with effusion. Pediatric Infectious Disease Journal1990;9(1):33-40. [CENTRAL: CN-00065358] [PMID: 2405348]">Giebink 1990</a>); </p> </li> <li> <p>studies in which not all participants had a diagnosis of OME (<a href="./references#CD015255-bbs2-0037" title="GluthMB , McDonaldDR , WeaverAL , BauchCD , BeattyCW , OrvidasLJ . Management of eustachian tube dysfunction with nasal steroid spray: a prospective, randomized, placebo-controlled trial. Archives of Otolaryngology--Head &amp; Neck Surgery2011;137(5):449-55. [CENTRAL: CN-00788460] [PMID: 21576556]NCT00279916. Short term relief of Eustachian tube dysfunction and serous otitis media using intranasal steroid sprays [Short term relief of Eustachian tube dysfunction and serous otitis media using intranasal steroid sprays: a randomized placebo-controlled study]. https://clinicaltrials.gov/show/NCT00279916 (first received 18 January 2006). [CENTRAL: CN-02035934] ">Gluth 2011</a>; <a href="./references#CD015255-bbs2-0050" title="ShapiroGG , BiermanCW , FurukawaCT , PiersonWE , BermanR , DonaldsonJ , et al. Treatment of persistent Eustachian tube dysfunction in children with aerosolized nasal dexamethasone phosphate versus placebo. Annals of Allergy1982;49(2):81-5. [CENTRAL: CN-00028488] [EMBASE: 1982193995] [PMID: 7103152]">Shapiro 1982</a>); </p> </li> <li> <p>adult participants (<a href="./references#CD015255-bbs2-0038" title="HanZ , ZhibinC , DengyuanW , XiaX , XiaonianZ , GuangqianX . The therapeutic effects of oral administration and intratympanic injection of glucocorticoid in the treatment of otitis media with effusion. Journal of Audiology and Speech Pathology2009;6:019. [CENTRAL: CN-00858712] ">Han 2009</a>). </p> </li> </ul> </li> <li> <p>Finally, we excluded one study for an incorrect comparator, as co‐interventions were not identical between the two groups (<a href="./references#CD015255-bbs2-0055" title="YeldandiV , MacLeodC , MulvaneyAM . Open-label, randomised, comparative study of usual care with or without clarithromycin suspension in serous otitis media with inflammation. In: 22nd International Congress of Chemotherapy; 2001 Jun 30-Jul 3; Amsterdam (the Netherlands). 2001. [ABSTRACT NO.: P10.009] [CENTRAL: CN-00453008] ">Yeldandi 2001</a>). </p> </li> </ul> </p> </section> </section> <section id="CD015255-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>All studies had at least some concerns regarding risk of bias. See <a href="#CD015255-fig-0003">Figure 3</a> for a summary of the risk of bias across all included studies, and <a href="#CD015255-fig-0004">Figure 4</a> for detailed assessments for each study. </p> <div class="figure" id="CD015255-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD015255-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD015255-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD015255-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD015255-sec-0068"> <h4 class="title">Allocation</h4> <p>Only five studies provided sufficient description of the randomisation process and methods used to conceal group allocation. We rated these at low risk of selection bias (<a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). Whilst a number of other studies appeared to use adequate randomisation methods, there was not a clear description of allocation concealment and we rated this domain at unclear risk of bias (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>). Many studies provided no information regarding the randomisation process, so we rated this domain at unclear risk of bias. </p> </section> <section id="CD015255-sec-0069"> <h4 class="title">Blinding</h4> <p>Ratings were mixed across the studies. We rated a large number of studies at high risk of performance and detection bias: as a placebo was not used, participants, study personnel and outcome assessors were aware of group allocation (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>). </p> <p>However, some studies did ensure that participants and outcome assessors remained blind to treatment allocation throughout the trial and we rated these at low risk of bias (<a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). </p> </section> <section id="CD015255-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>We rated this domain at low risk of bias overall, as we judged 13 studies to have no concerns over attrition bias. However, we noted that attrition was, understandably, more of a problem in the studies with a longer duration of follow‐up, including <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> and <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>. </p> </section> <section id="CD015255-sec-0071"> <h4 class="title">Selective reporting</h4> <p>For most studies, we were unable to identify a published protocol. Therefore, we could not assess whether the authors had adhered to their planned analysis when reporting the results. Consequently, we rated many studies at unclear risk of bias for this domain. Three studies did report according to their pre‐specified analysis plan (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). We rated three studies at high risk of bias, due to lack of reporting of pre‐specified outcome measures (<a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>), or unclear and selective reporting of outcome measures, which precluded meta‐analysis (<a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>). </p> </section> <section id="CD015255-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p>We rated many studies at high risk of bias for this domain due to the short follow‐up time, which would not allow an appropriate comparison of the two treatment strategies (steroids versus watchful waiting or placebo). We considered that a follow‐up time of at least three months was required, in order to give sufficient time for the potential for natural resolution of the disease. However, this duration of follow‐up was not completed for most of the studies in this review. </p> </section> </section> <section id="CD015255-sec-0073"> <h3 class="title" id="CD015255-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD015255-tbl-0001"><b>Summary of findings 1</b> Oral steroids compared to placebo for otitis media with effusion (OME) in children</a>; <a href="./full#CD015255-tbl-0003"><b>Summary of findings 2</b> Oral steroids compared to no treatment for otitis media with effusion (OME) in children</a>; <a href="./full#CD015255-tbl-0004"><b>Summary of findings 3</b> Topical (intranasal) steroids compared to placebo for otitis media with effusion (OME) in children</a>; <a href="./full#CD015255-tbl-0005"><b>Summary of findings 4</b> Topical (intranasal) steroids compared to no treatment for otitis media with effusion (OME) in children</a> </p> <section id="CD015255-sec-0074"> <h4 class="title">Oral steroids versus placebo</h4> <p>Eleven studies assessed this comparison (<a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>; <a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a>; <a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a>; <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a>; <a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>; <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>; <a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a>; <a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a>). However, our outcomes of interest were not reported by all studies, therefore very limited meta‐analysis was possible. See <a href="./full#CD015255-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD015255-sec-0075"> <h5 class="title">Hearing ‐ return to normal hearing</h5> <section id="CD015255-sec-0076"> <h6 class="title">Up to six weeks</h6> <p>One study assessed the proportion of children in whom hearing was 'acceptable' in at least one ear after five weeks of follow‐up (<a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>). The risk ratio (RR) for a return to normal hearing in those who received oral steroids was 1.22 (95% confidence interval (CI) 0.92 to 1.60; absolute effect 32.8% of participants in the placebo group, compared to 40% in the steroid group; number needed to treat (NNT) 14; 1 study, 363 participants; <a href="./references#CD015255-fig-0005" title="">Analysis 1.1</a>; low‐certainty evidence). A similar effect size was seen when adjusting for baseline differences (<a href="./references#CD015255-fig-0006" title="">Analysis 1.2</a>). </p> <p>One further study reported data at this time point, but we were unable to include the data in a meta‐analysis, as the denominator for each group was unclear, and there were discrepancies in the size of the groups reported in the article. <a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a> assessed the proportion of children whose hearing returned to normal using speech awareness thresholds or speech reception thresholds. A significant difference was reported for children assessed with speech awareness thresholds (86% of ears with normal hearing amongst those who received steroids, compared to 42% of ears with normal hearing amongst those who received placebo), but not for those children assessed with speech reception thresholds (92% of ears for those who received steroids, compared to 89% of ears for those who received placebo). It should be noted that 33% of ears had normal hearing at baseline, and that all participants in this study also received antibiotics. </p> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> provided some data suitable for subgroup analysis for this outcome. We assessed whether the use of oral steroids had different effects in children with allergies (atopy), but the effect estimates were similar for both groups (<a href="./references#CD015255-fig-0026" title="">Analysis 1.22</a>). </p> </section> <section id="CD015255-sec-0077"> <h6 class="title">Up to three months</h6> <p>One study assessed the proportion of children with complete resolution of the air‐bone gap after two months of follow‐up. The difference between the groups was trivial, although the confidence intervals were wide (RR 0.98, 95% CI 0.61 to 1.58; 1 study, 99 participants; <a href="./references#CD015255-fig-0007" title="">Analysis 1.3</a>; very low‐certainty evidence). </p> </section> <section id="CD015255-sec-0078"> <h6 class="title">Up to one year</h6> <p>Finally, <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> also conducted follow‐up assessment at 12 months after completion of a seven‐day course of steroids. The risk ratio for return to normal hearing in those who had received steroids was 1.14 (95% CI 0.97 to 1.33; 1 study, 332 participants; <a href="./references#CD015255-fig-0008" title="">Analysis 1.4</a>; moderate‐certainty evidence). However, it should be noted that the proportion of children in the control group with normal hearing was also high (61.1% of children receiving placebo, compared to 69.4% of children receiving steroids). </p> </section> </section> <section id="CD015255-sec-0079"> <h5 class="title">Hearing ‐ hearing threshold</h5> <section id="CD015255-sec-0080"> <h6 class="title">Up to six weeks</h6> <p>Final hearing threshold was also reported by <a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>, but the difference between the two groups was trivial after short‐term follow‐up (mean difference (MD) 0.56 dB HL lower, 95% CI ‐2.55 to 1.43; 1 study, 364 participants; <a href="./references#CD015255-fig-0009" title="">Analysis 1.5</a>; low‐certainty evidence). A similar effect was seen after adjusting for confounders (<a href="./references#CD015255-fig-0010" title="">Analysis 1.6</a>). </p> <p><a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a> also reported this outcome, but we could not include the data in a meta‐analysis. The authors reported a significant difference in speech awareness thresholds at two weeks of follow‐up (mean difference ‐5.8 dB HL better for those receiving steroids), but no significant change in speech reception thresholds (mean difference +1 dB HL worse for those receiving steroids). </p> </section> </section> <section id="CD015255-sec-0081"> <h5 class="title">Disease‐specific quality of life</h5> <p>One study assessed OME‐specific quality of life, using the OM8‐30 questionnaire (<a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>). This was completed by parents, on behalf of the child. As described above, limited details on the method for scoring this questionnaire were available, and we were unable to identify a minimally important difference. It appears that the scores are reported on a standardised scale, so we have used Cohen's effect sizes to help interpret this measure. </p> <section id="CD015255-sec-0082"> <h6 class="title">Up to six weeks</h6> <p>After five weeks of follow‐up, OM8‐30 scores were 0.16 higher (worse) in the oral steroid group (95% CI ‐0.07 to 0.39; 1 study, 359 participants; <a href="./references#CD015255-fig-0011" title="">Analysis 1.7</a>; low‐certainty evidence). It is unclear how clinically significant this difference is, as the authors do not report the full range for this score, nor suggest what difference in score would be regarded as clinically meaningful. If we assume that this is reported on a standardised scale, then an effect size of 0.16 would be considered a trivial difference between the two groups. </p> </section> <section id="CD015255-sec-0083"> <h6 class="title">Up to one year</h6> <p>The same study assessed disease‐specific quality of life at 12 months of follow‐up. The mean difference between the groups was 0.07 points higher (worse) for those receiving steroids, but the confidence intervals were wide (‐0.20 to 0.34; 1 study, 304 participants; <a href="./references#CD015255-fig-0012" title="">Analysis 1.8</a>; moderate‐certainty evidence). </p> </section> </section> <section id="CD015255-sec-0084"> <h5 class="title">Adverse events</h5> <p>Adverse events were reported inconsistently across the studies. 'Systemic corticosteroid side effects' was one of our primary outcomes. However, it was often unclear if reported side effects were considered to be related to corticosteroid use or not. We thus took an inclusive approach to adverse event reporting and extracted data on all adverse effects reported by the studies. These are reported in <a href="./full#CD015255-tbl-0002">Table 1</a>. </p> </section> <section id="CD015255-sec-0085"> <h5 class="title">Presence/persistence of OME</h5> <p>Eleven studies reported this outcome, at various follow‐up times. However, we noted that different definitions of 'persistent effusion' were used across the studies (see <a href="#CD015255-sec-0047">Included studies</a> above). </p> <section id="CD015255-sec-0086"> <h6 class="title">Up to six weeks</h6> <p>Persistence of OME at up to six weeks may be slightly lower in those who receive steroids. However, the evidence was very uncertain and most children in both groups still had a persistent effusion at this time point (82.3% in the placebo group, compared to 71.8% in the steroid group, RR 0.72, 95% CI 0.51 to 1.02; 7 studies, 786 participants; I<sup>2</sup> = 90%; <a href="./references#CD015255-fig-0013" title="">Analysis 1.9</a>; very low‐certainty evidence). As anticipated, there was substantial heterogeneity in this analysis, which resolved slightly when considering the different definitions of 'persistence' used across the studies. Sensitivity analyses to account for different ways of assessing persistence made little difference to the overall effect estimates (<a href="./references#CD015255-fig-0014" title="">Analysis 1.10</a>; <a href="./references#CD015255-fig-0015" title="">Analysis 1.11</a>). </p> <p>The study <a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> provided a small amount of information regarding our subgroups of interest for this outcome. We were able to analyse whether the effect size varied for children with allergies (positive skin tests) versus those without and for children aged &lt; 4 versus those aged ≥ 4 years (<a href="./references#CD015255-fig-0027" title="">Analysis 1.23</a>; <a href="./references#CD015255-fig-0028" title="">Analysis 1.24</a>). However, we did not find evidence of a difference between these subgroups. </p> </section> <section id="CD015255-sec-0087"> <h6 class="title">Up to three months</h6> <p>Only three studies assessed persistence of OME at this time point. The proportion of children with persistent OME was also slightly lower for those receiving steroids, but the confidence intervals were very wide (proportion with persistent OME 68% versus 55%; RR 0.81, 95% CI 0.50 to 1.30; 3 studies, 211 participants; I<sup>2</sup> = 80%; <a href="./references#CD015255-fig-0016" title="">Analysis 1.12</a>; very low‐certainty evidence). Again, sensitivity analyses to account for different correlations in the data between ears of the same individual, or different ways of assessing persistence, made little difference to the overall estimate (<a href="./references#CD015255-fig-0017" title="">Analysis 1.13</a>; <a href="./references#CD015255-fig-0018" title="">Analysis 1.14</a>; <a href="./references#CD015255-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD015255-sec-0088"> <h6 class="title">Up to one year</h6> <p>Two studies reported the persistence of OME at up to 12 months. The difference in results from the two studies was considerable, and the evidence is therefore very uncertain. Pooling of the data resulted in a very substantial I<sup>2</sup> value, and the confidence intervals for the fixed‐effect and random‐effects model were very different. We therefore took the decision not to pool these data. </p> <p>One study showed a modest benefit from oral steroids, but the rate of persistent effusion was still high in both groups at 12 months of follow‐up (93.8% in the placebo group, 80.5% in the steroid group, RR 0.86, 95% CI 0.79 to 0.94; 1 study, 303 participants; <a href="./references#CD015255-fig-0020" title="">Analysis 1.16</a>). </p> <p>The second study showed a very marked benefit from oral steroids, with a RR of 0.18 (95% CI 0.06 to 0.54; absolute effects show persistence in 67% of children receiving placebo, compared to 12% of children receiving steroids; 1 study, 49 participants; <a href="./references#CD015255-fig-0020" title="">Analysis 1.16</a>). Children included in this trial had not responded to two courses of oral antibiotics, therefore may represent a subpopulation of all children with OME. However, it is also unclear how 'persistence' of OME was defined. </p> </section> </section> <section id="CD015255-sec-0089"> <h5 class="title">Generic quality of life</h5> <p>One study used two different questionnaires to assess generic quality of life.</p> <section id="CD015255-sec-0090"> <h6 class="title">Up to six weeks</h6> <p>The Pediatric Quality of Life Inventory (PedsQL) considers physical functioning, emotional functioning, social functioning and school functioning (<a href="https://www.pedsql.org/" target="_blank">www.pedsql.org/</a>). The raw scores are transformed to a scale of 1 to 100, with higher scores representing better quality of life. The minimally important difference has been suggested to be a change of 4.5 points. A trivial difference was seen between the groups at this time point (MD ‐0.9, 95% CI ‐3.86 to 2.06; 1 study, 358 participants; <a href="./references#CD015255-fig-0022" title="">Analysis 1.18</a>; low‐certainty evidence). </p> <p>The Health Utilities Index 3 (HUI3) was also used (<a href="./references#CD015255-bbs2-0066" title="FeenyD , FurlongW , TorranceGW , GoldsmithCH , ZhuZ , DePauw S et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care2002;40(2):113-28.">Feeny 2002</a>). This assesses health on a scale of 0 (dead) to 1 (perfect health). For this analysis, the study authors used a dichotomous scale, comparing the proportion of children with a score of perfect health between the two groups. The risk ratio for a perfect score in those receiving steroids compared to placebo was 1.06 (95% CI 0.70 to 1.60; absolute effects 21.3% in the control group, compared to 22.6% in the steroid group; 1 study, 319 participants; <a href="./references#CD015255-fig-0024" title="">Analysis 1.20</a>; very low‐certainty evidence). </p> </section> <section id="CD015255-sec-0091"> <h6 class="title">Up to one year</h6> <p>Results were similar at up to one‐year follow‐up, with both questionnaires indicating a very small or trivial difference between the two groups (PedsQL MD ‐0.27, 95% CI ‐2.74 to 3.28; 1 study, 303 participants; <a href="./references#CD015255-fig-0023" title="">Analysis 1.19</a>; moderate‐certainty evidence, and HUI3 RR 1.10, 95% CI 0.79 to 1.53; 1 study, 292 participants; <a href="./references#CD015255-fig-0025" title="">Analysis 1.21</a>; moderate‐certainty evidence). </p> </section> </section> <section id="CD015255-sec-0092"> <h5 class="title">Number of doctor‐diagnosed episodes of acute otitis media</h5> <section id="CD015255-sec-0093"> <h6 class="title">Up to six weeks</h6> <p>This outcome was only assessed at very short‐term follow‐up. The pooled result showed little difference in the proportion of children who developed acute otitis media between the two groups, although the confidence interval was very wide and the evidence was very uncertain (absolute effects 5.9% in the placebo group compared to 5.7% in the steroid group; RR 0.97, 95% CI 0.31 to 3.10; 3 studies, 207 participants; I<sup>2</sup> = 54%; <a href="./references#CD015255-fig-0021" title="">Analysis 1.17</a>; very low‐certainty evidence). </p> </section> </section> <section id="CD015255-sec-0094"> <h5 class="title">Other outcomes</h5> <p>No data were identified regarding receptive or expressive language skills, cognitive development, psychosocial outcomes, listening skills, parental stress or vestibular function. </p> </section> </section> <section id="CD015255-sec-0095"> <h4 class="title">Oral steroids versus no treatment</h4> <p>Three studies provided data for this comparison (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>; <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a>). However, the only outcome assessed was the persistence of OME. See <a href="./full#CD015255-tbl-0003">summary of findings Table 2</a>. </p> <section id="CD015255-sec-0096"> <h5 class="title">Presence/persistence of OME</h5> <section id="CD015255-sec-0097"> <h6 class="title">Up to six weeks</h6> <p>A single study assessed the persistence of OME after four weeks of treatment. The risk ratio for persistence in those who had received oral steroids was 0.48 (95% CI 0.32 to 0.73; 82.5% of children receiving no treatment, compared to 39.6% of children receiving steroids; 1 study, 80 participants; <a href="./references#CD015255-fig-0029" title="">Analysis 2.1</a>; very low‐certainty evidence). </p> </section> <section id="CD015255-sec-0098"> <h6 class="title">Up to three months</h6> <p>One further study assessed this outcome after three months of follow‐up and found a trivial difference between the two groups (persistence in 86% of children receiving no treatment, compared to 85% of those receiving steroids; RR 0.99, 95% CI 0.88 to 1.11; 1 study, 192 participants; <a href="./references#CD015255-fig-0030" title="">Analysis 2.2</a>; low‐certainty evidence). </p> </section> <section id="CD015255-sec-0099"> <h6 class="title">Up to one year</h6> <p>Two studies conducted slightly longer‐term follow‐up, and assessed this outcome at between three and nine months. Overall, the risk ratio for persistence was 1.02 (95% CI 0.89 to 1.17; 73% of children receiving no treatment, compared to 74% of those receiving steroids; 2 studies, 258 participants; <a href="./references#CD015255-fig-0031" title="">Analysis 2.3</a>; low‐certainty evidence). </p> </section> </section> <section id="CD015255-sec-0100"> <h5 class="title">Adverse events</h5> <p>Both <a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a> and <a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a> stated that no adverse effects of oral steroids were reported in study participants. <a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a> did not report on adverse events. </p> </section> <section id="CD015255-sec-0101"> <h5 class="title">Other outcomes</h5> <p>No data were identified regarding hearing, disease‐specific or generic quality of life, receptive or expressive language skills, cognitive development, psychosocial outcomes, listening skills, parental stress, vestibular function or the number of doctor‐diagnosed episodes of otitis media. </p> </section> </section> <section id="CD015255-sec-0102"> <h4 class="title">Topical (intranasal) steroids versus placebo</h4> <p>Six studies assessed this comparison (<a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a>; <a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a>; <a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a>; <a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>; <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a>; <a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). However, not all studies reported on our outcomes of interest. See <a href="./full#CD015255-tbl-0004">summary of findings Table 3</a>. </p> <section id="CD015255-sec-0103"> <h5 class="title">Hearing</h5> <p>No studies used our preferred primary outcome of the proportion of children with normal hearing. The only available data considered mean final hearing threshold. </p> <section id="CD015255-sec-0104"> <h6 class="title">Hearing threshold</h6> <section id="CD015255-sec-0105"> <p><b>Up to three months</b></p> <p>One study reported on the change in hearing threshold after two months of follow‐up. Very little difference was seen between the two groups, with a mean difference of ‐0.3 dB HL for those who received steroids, but the evidence was very uncertain (95% CI ‐6.05 to 5.45; 1 study, 78 participants; <a href="./references#CD015255-fig-0032" title="">Analysis 3.1</a>; very low‐certainty evidence). Sensitivity analyses varying the correlation between ears of the same individual made little difference to the estimate (<a href="./references#CD015255-fig-0033" title="">Analysis 3.2</a>; <a href="./references#CD015255-fig-0034" title="">Analysis 3.3</a>). </p> <p>A second study assessed the final hearing threshold after three months of follow‐up and found a benefit to steroids but, again, the evidence was very uncertain (MD ‐14.95, 95% CI ‐17.32 to ‐12.58; 1 study, 40 participants; <a href="./references#CD015255-fig-0035" title="">Analysis 3.4</a>; very low‐certainty evidence). </p> <p>The study <a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a> provided no useable data for meta‐analysis. However, the authors stated that <i>"there was a greater improvement in hearing levels in the treatment group compared to the controls. This difference was most marked at the end of the study [12 weeks]"</i>. </p> </section> <section id="CD015255-sec-0106"> <p><b>Up to one year</b></p> <p><a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a> assessed the pure tone average hearing threshold after 24 weeks of follow‐up. However, no variance was reported and the number of participants in each group was not stated. The authors' own analysis indicated that there was a significant difference between the two groups, with a mean hearing threshold of 5.2 dB HL in those receiving steroids and 11.6 dB HL for those receiving placebo (1 study, 62 participants; very low‐certainty evidence). </p> </section> </section> </section> <section id="CD015255-sec-0107"> <h5 class="title">Disease‐specific quality of life</h5> <p>A single study assessed this outcome, using the sum of seven domains from the OM8‐30 questionnaire (behaviour, speech and language, school prospects, parental quality of life, global health, respiratory symptoms and ear problems). The full range of scores for this questionnaire was not available, nor was the minimally important difference. Lower scores are stated to represent better quality of life. We assume that results are presented with a form of standardised score and can be interpreted using Cohen's effect sizes. </p> <section id="CD015255-sec-0108"> <h6 class="title">Up to three months</h6> <p>The mean difference in score was ‐0.07 (95% CI ‐0.49 to 0.35; 1 study, 82 participants; low‐certainty evidence). We considered that this was likely to represent a trivial difference between the two groups. </p> </section> <section id="CD015255-sec-0109"> <h6 class="title">Up to one year</h6> <p>The mean difference in score was 0.05 (95% CI ‐0.36 to 0.46; 1 study, 82 participants; low‐certainty evidence). Again, we thought this was likely to represent a trivial difference between the two groups. </p> </section> </section> <section id="CD015255-sec-0110"> <h5 class="title">Presence/persistence of OME</h5> <section id="CD015255-sec-0111"> <h6 class="title">Up to six weeks</h6> <p>One study assessed this outcome after one month and found very little difference between the groups (82% children in the no treatment group with persistence, compared to 80% of children in the nasal steroids group; RR 0.98, 95% CI 0.80 to 1.20; 1 study, 89 participants; <a href="./references#CD015255-fig-0038" title="">Analysis 3.7</a>; very low‐certainty evidence). Accounting for different levels of correlation between ears of the same individual made little difference to the overall estimates (<a href="./references#CD015255-fig-0039" title="">Analysis 3.8</a>; <a href="./references#CD015255-fig-0040" title="">Analysis 3.9</a>). </p> </section> <section id="CD015255-sec-0112"> <h6 class="title">Up to three months</h6> <p>Three studies reported at this time point. Overall, nasal steroids may reduce the chance of persistent OME after up to three months of follow‐up, but the evidence was very uncertain. Of children receiving placebo, 58% had persistent OME, compared to 46% of those receiving intranasal steroids (RR 0.80, 95% CI 0.51 to 1.26; 3 studies, 286 participants; <a href="./references#CD015255-fig-0041" title="">Analysis 3.10</a>; low‐certainty evidence). </p> </section> <section id="CD015255-sec-0113"> <h6 class="title">Up to one year</h6> <p>Two studies assessed the persistence of OME after longer‐term follow‐up. However, the results were very different, therefore we took the decision not to pool the data. </p> <p> <ul id="CD015255-list-0030"> <li> <p><a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a> assessed the persistence of OME after six months of follow‐up. Persistence was reduced for those who had received nasal mometasone furoate for 24 weeks (50% of those receiving placebo, compared to 7% of those receiving steroids; RR 0.13, 95% CI 0.03 to 0.53; 1 study, 62 participants; <a href="./references#CD015255-fig-0044" title="">Analysis 3.13</a>). All participants in this study had adenoid hypertrophy and had failed to respond to previous treatments, which may account for some clinical heterogeneity between the two studies. </p> </li> <li> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> assessed persistence at nine months of follow‐up for children who had received three months of mometasone furoate. Of children in the placebo group, 35% had persistent effusion, compared to 44% of those who received steroids (RR 1.28, 95% CI 0.85 to 1.93; 1 study, 144 participants; <a href="./references#CD015255-fig-0044" title="">Analysis 3.13</a>). </p> </li> </ul> </p> <p>Overall, we considered the evidence for this outcome to be very uncertain, as we were unable to pool the data, and the studies indicated opposing directions of effect. </p> </section> </section> <section id="CD015255-sec-0114"> <h5 class="title">Adverse effects</h5> <p>As described above, adverse effects were inconsistently reported across the different studies. It was not possible to discern whether authors considered certain reported symptoms to be related to the treatment. Therefore, we took an inclusive approach to data collection for adverse events and show all reported adverse effects in <a href="#CD015255-tbl-0008">Table 4</a>. </p> </section> <section id="CD015255-sec-0115"> <h5 class="title">Other outcomes</h5> <p>No data were identified regarding receptive language skills, speech development, cognitive development, psychosocial outcomes, listening skills, generic quality of life, parental stress, vestibular function or doctor‐diagnosed episodes of otitis media. </p> </section> </section> <section id="CD015255-sec-0116"> <h4 class="title">Topical (intranasal) steroids versus no treatment</h4> <p>Seven studies assessed this comparison (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>; <a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a>; <a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a>; <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a>; <a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a>; <a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a>), including one three‐armed trial, which also provided data for the comparison of oral steroids and no treatment (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>). See <a href="./full#CD015255-tbl-0005">summary of findings Table 4</a>. </p> <section id="CD015255-sec-0117"> <h5 class="title">Hearing</h5> <p>No data were reported regarding the return to normal hearing.</p> <section id="CD015255-sec-0118"> <h6 class="title">Final hearing threshold</h6> <section id="CD015255-sec-0119"> <p><b>Up to six weeks</b></p> <p>A single study reported on the final hearing threshold (as assessed with the air‐bone gap) after one month of follow‐up, and found a mean difference of ‐1.95 dB HL (95% CI ‐3.85 to ‐0.05; 1 study, 168 participants; <a href="./references#CD015255-fig-0047" title="">Analysis 4.1</a>; very low‐certainty evidence). </p> <p><a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a> also provided a description of final hearing threshold, but with no measure of the variance in the two groups. This could not be included in a meta‐analysis. Nonetheless, the authors reported a significant difference (P &lt; 0.05) between the two groups, with a mean air‐bone gap of 8 dB for the group receiving steroids, compared to 20 dB for those receiving no treatment. </p> </section> <section id="CD015255-sec-0120"> <p><b>Up to three months</b></p> <p>Again, <a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a> provided a description of final hearing threshold, but with no measure of the variance in the two groups. After nine weeks of follow‐up, there was no longer a significant difference between the two groups, with an air‐bone gap of 18 dB in those receiving steroids, compared to 24 dB in the no treatment group (P &gt; 0.05; 1 study, 92 participants; very low‐certainty evidence). </p> </section> </section> </section> <section id="CD015255-sec-0121"> <h5 class="title">Presence/persistence of OME</h5> <section id="CD015255-sec-0122"> <h6 class="title">Up to six weeks</h6> <p>Overall, nasal steroids may reduce the proportion of children with persistent OME at up to one month of follow‐up, but the evidence was very uncertain. The pooled results from five studies showed a risk ratio of 0.62 (95% CI 0.44 to 0.86; 70% of children in the control group, compared to 44% of children in the nasal steroid group; 5 studies, 562 participants; I<sup>2</sup> = 74%; <a href="./references#CD015255-fig-0048" title="">Analysis 4.2</a>; very low‐certainty evidence). Sensitivity analyses accounting for different correlations between ears of the same individual showed very similar results (<a href="./references#CD015255-fig-0049" title="">Analysis 4.3</a>; <a href="./references#CD015255-fig-0050" title="">Analysis 4.4</a>). </p> </section> <section id="CD015255-sec-0123"> <h6 class="title">Up to three months</h6> <p>Two studies looked at the persistence of OME at up to three months and also found a reduction for those who received steroids, but the evidence was very uncertain (RR 0.72, 95% CI 0.57 to 0.91; 81% of children in the control group, compared to 59% of children in the steroid group; 2 studies, 134 participants; I<sup>2</sup> = 0%; <a href="./references#CD015255-fig-0051" title="">Analysis 4.5</a>; very low‐certainty evidence). Again, sensitivity analyses accounting for different correlations between ears showed minimal change (<a href="./references#CD015255-fig-0052" title="">Analysis 4.6</a>; <a href="./references#CD015255-fig-0053" title="">Analysis 4.7</a>). </p> </section> </section> <section id="CD015255-sec-0124"> <h5 class="title">Adverse events</h5> <p>Data pertaining to potential adverse effects of treatment are described in <a href="#CD015255-tbl-0008">Table 4</a>. </p> </section> <section id="CD015255-sec-0125"> <h5 class="title">Other outcomes</h5> <p>No data were identified regarding disease‐specific or generic quality of life, receptive language skills, speech development, cognitive development, psychosocial outcomes, listening skills, parental stress, vestibular function or doctor‐diagnosed episodes of otitis media. </p> <p>The results of all sensitivity analyses are presented in <a href="#CD015255-tbl-0009">Table 5</a>. </p> <div class="table" id="CD015255-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analysis result (RR and 95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis result (RR and 95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Oral steroid versus placebo</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 Persistence of OME (very short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.51 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.82 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 Persistence of OME (very short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.51 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies with any concern over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.48 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 (0.50 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.67 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Oral steroid versus no treatment</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 Persistence of OME (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.89 to 1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.90 to 1.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Nasal steroid versus placebo</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.10 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.51 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.69 to 1.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.10 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.51 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies with any concern over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.63 to 1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Nasal steroid versus no treatment</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2 Persistence of OME (very short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.44 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (0.50 to 0.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2 Persistence of OME (very short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.44 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.46 to 1.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.57 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.57 to 0.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.57 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies with any concern over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.50 to 0.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.57 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 [0.55 to 1.16)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio</p> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015255-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015255-sec-0126"></div> <section id="CD015255-sec-0127"> <h3 class="title" id="CD015255-sec-0127">Summary of main results</h3> <section id="CD015255-sec-0128"> <h4 class="title">Oral steroids versus placebo</h4> <p>Oral steroids probably make little difference to the proportion of children whose hearing returns to normal after one year of follow‐up. A similar effect is seen at earlier time points, although the evidence is less certain. The evidence also shows that there is likely to be little or no difference in disease‐specific quality of life and generic quality of life after one year of follow‐up. Overall, persistence of OME did appear to be lower in those children who received oral steroids at up to six weeks, up to three months and up to one year of follow‐up, but the evidence was less certain. It should also be noted that persistent disease was common in both groups at all follow‐up times and the size of any benefit may be small. The evidence regarding episodes of acute otitis media was uncertain, but there may be little difference between those who receive steroids and those who do not. The evidence on adverse effects (including systemic corticosteroid side effects) was very uncertain, but we did not identify major concerns over side effects. </p> </section> <section id="CD015255-sec-0129"> <h4 class="title">Oral steroids versus no treatment</h4> <p>The evidence for this comparison was all low‐ or very low‐certainty. After six weeks of follow‐up, fewer children who received oral steroids had persistent OME, but the difference was trivial after 3 to 12 months of follow‐up. Very limited information was available on adverse effects of treatment, so we were unable to draw any conclusions about the risk of side effects. No other outcomes were assessed for this comparison. </p> </section> <section id="CD015255-sec-0130"> <h4 class="title">Topical (intranasal) steroids versus placebo</h4> <p>No studies reported on our preferred measure of hearing, the return to normal hearing. The effect of nasal steroids on final hearing threshold was very uncertain. Nasal steroids may have little impact on disease‐specific quality of life at up to 12 months of follow‐up. The effect on persistence of OME was uncertain, with studies showing no difference at one month of follow‐up, some benefit after three months of follow‐up and conflicting results at 12 months of follow‐up (one study showing benefit, another showing potential harm). As above, the evidence on adverse effects (including systemic corticosteroid side effects and nasal irritation) was very uncertain, but we did not identify major concerns over side effects. </p> </section> <section id="CD015255-sec-0131"> <h4 class="title">Topical (intranasal) steroids versus no treatment</h4> <p>Again, we did not identify any data on the return to normal hearing, and the evidence on final hearing threshold was very uncertain. Persistence of OME was lower for those children who received nasal steroids at up to six weeks and up to three months, but the evidence was also very uncertain. Very limited information was available on adverse effects of treatment, so we were unable to draw any conclusions about the risk of side effects. No other outcomes were assessed for this comparison. </p> </section> </section> <section id="CD015255-sec-0132"> <h3 class="title" id="CD015255-sec-0132">Overall completeness and applicability of evidence</h3> <p>It should be noted that the studies included in this review used a variety of different doses, preparations and duration of oral and nasal steroids. We were unable to determine if the efficacy (or harms) of these different regimens varied. However, this may reflect standard clinical practice, where a range of different doses and durations of treatment may be used. </p> <p>Although we included 26 studies in this review, very limited pooling of data was possible. We did not identify any evidence on developmental outcomes, including language skills, cognition and psychosocial outcomes. However, it is likely that these outcomes are of major importance to children with OME and their parents. The only outcome that was consistently reported by most studies was the presence of OME. However, there were sparse data on patient‐reported outcomes, such as quality of life. </p> <p>Few studies reported on hearing and almost none reported our preferred outcome measure, the number of children who returned to normal hearing. We have concerns that assessment of hearing using the mean difference in final hearing threshold (or mean change in hearing threshold) may not be the most appropriate way to assess hearing. OME has a high spontaneous resolution rate. Consequently, we would anticipate that the change in hearing threshold for most children will be similar across the groups, as many children will improve with or without treatment. Therefore, even if a subset of children had substantial benefit from the intervention, the overall mean difference between the two groups would appear to be small. When assessed using the mean difference, the marked benefit seen in a subgroup of participants is ‘diluted’ by the children who get better regardless of treatment. Therefore, an apparently small mean difference between the two groups may actually be consistent with a substantial change in the number of children in whom hearing returns to normal. </p> <p>As discussed below, a number of studies included in this review treated participants in the study with concomitant antibiotics. This may impact on the overall results, if antibiotics were considered to have a strong effect on OME, or if there may be synergistic effects between antibiotics and steroids. </p> </section> <section id="CD015255-sec-0133"> <h3 class="title" id="CD015255-sec-0133">Quality of the evidence</h3> <p>Most of the evidence included in this review was considered low‐ or very low‐certainty. This was predominantly due to the small size of the studies included, which led to wide confidence intervals and imprecision in the overall effect estimates. We also identified a number of concerns over the risk of bias with some of the studies included, which was reflected in the GRADE ratings. </p> </section> <section id="CD015255-sec-0134"> <h3 class="title" id="CD015255-sec-0134">Potential biases in the review process</h3> <p>We are aware that a number of studies included in this review administered a course of antibiotics to all participants in the study. Therefore, the comparisons of interest were (as pre‐specified in our review protocol) of steroids versus no treatment or placebo, but with a background treatment of antibiotics. There is the potential, therefore, that this additional treatment may introduce some bias in the effect estimates. Firstly, there is the possibility that the use of antibiotics may mask a potential benefit (or harm) from steroids. If antibiotics had a strong effect on symptoms of OME, then we would expect substantial change in both the intervention and control groups ‐ and any additional benefit (or harm) of steroids may not be seen. The companion review in this suite, which addresses the use of antibiotics for OME, did find some evidence for a reduction in persistence of OME with the use of antibiotics (<a href="./references#CD015255-bbs2-0093" title="MulvaneyCA , GalbraithK , MacKeithS , MaromT , DanielM , VenekampRP , et al. Antibiotics for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015254. [DOI: 10.1002/14651858.CD015254]">Mulvaney 2022a</a>). A second possibility is that there may be some synergistic (or antagonistic) effects between the two medications, such that the use of steroids with antibiotics is more (or less) effective than steroids used alone. Therefore, the inclusion of these studies may have an impact on the results of this review, although it was in keeping with our protocol. </p> </section> <section id="CD015255-sec-0135"> <h3 class="title" id="CD015255-sec-0135">Agreements and disagreements with other studies or reviews</h3> <p>The conclusions of the review are similar to those of the previous Cochrane Review on this topic, which identified a potential short‐term benefit of oral steroids for 'resolution of OME', but no evidence of benefit for hearing or long‐term effects (<a href="./references#CD015255-bbs2-0120" title="SimpsonSA , LewisR , van derVoortJ , ButlerCC . Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. Cochrane Database of Systematic Reviews2011, Issue 5. Art. No: CD001935. [DOI: 10.1002/14651858.CD001935.pub3]">Simpson 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015255-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-FIG-01" target="_blank"><b></b></a></p> </div><img alt="The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool" data-id="CD015255-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-01.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-FIG-02" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD015255-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-FIG-03" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD015255-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD015255-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 1: Normal hearing (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 1: Normal hearing (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 2: Normal hearing (very short‐term ‐ up to 6 weeks, adjusted OR)" data-id="CD015255-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 2: Normal hearing (very short‐term ‐ up to 6 weeks, adjusted OR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 3: Normal hearing defined as complete improvement in air‐bone gap (short‐term ‐ up to 3 months)" data-id="CD015255-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 3: Normal hearing defined as complete improvement in air‐bone gap (short‐term ‐ up to 3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 4: Normal hearing (medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 4: Normal hearing (medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 5: Hearing threshold (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 5: Hearing threshold (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 6: Hearing threshold (difference in adjusted mean, very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 6: Hearing threshold (difference in adjusted mean, very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 7: Disease‐specific quality of life (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 7: Disease‐specific quality of life (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 8: Disease‐specific quality of life (medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 8: Disease‐specific quality of life (medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 9: Persistence of OME (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 9: Persistence of OME (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 10: Sensitivity analysis: persistence of OME (very short‐term); persistence in all affected ears (Berman 1990)" data-id="CD015255-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 10: Sensitivity analysis: persistence of OME (very short‐term); persistence in all affected ears (Berman 1990) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 11: Sensitivity analysis: persistence of OME (very short‐term); effusion in both ears (Niederman 1984)" data-id="CD015255-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 11: Sensitivity analysis: persistence of OME (very short‐term); effusion in both ears (Niederman 1984) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 12: Persistence of OME (short‐term ‐ up to 3 months); ICC = 0.5" data-id="CD015255-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 12: Persistence of OME (short‐term ‐ up to 3 months); ICC = 0.5 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 13: Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0" data-id="CD015255-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 13: Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 14: Sensitivity analysis: persistence of OME (short‐term); ICC = zero" data-id="CD015255-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 14: Sensitivity analysis: persistence of OME (short‐term); ICC = zero </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 15: Sensitivity analysis: persistence of OME (short‐term); persistence in all affected ears (Macknin 1985)" data-id="CD015255-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 15: Sensitivity analysis: persistence of OME (short‐term); persistence in all affected ears (Macknin 1985) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 16: Persistence of OME (medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 16: Persistence of OME (medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 17: Acute otitis media (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 17: Acute otitis media (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 18: Generic health‐related quality of life (PedsQL, very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0022" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 18: Generic health‐related quality of life (PedsQL, very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 19: Generic health‐related quality of life (PedsQL, medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0023" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 19: Generic health‐related quality of life (PedsQL, medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 20: Generic health‐related quality of life (HU13, very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0024" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 20: Generic health‐related quality of life (HU13, very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 21: Generic health‐related quality of life (HU13, medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0025" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 21: Generic health‐related quality of life (HU13, medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 22: Subgroup analysis: normal hearing: allergy versus none (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0026" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 22: Subgroup analysis: normal hearing: allergy versus none (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 23: Subgroup analysis: persistence of OME: allergy versus none (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0027" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 23: Subgroup analysis: persistence of OME: allergy versus none (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral steroid versus placebo, Outcome 24: Subgroup analysis: persistence of OME: age &lt; 4 versus ≥ 4 (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0028" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Oral steroid versus placebo, Outcome 24: Subgroup analysis: persistence of OME: age &lt; 4 versus ≥ 4 (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral steroid versus no treatment, Outcome 1: Persistence of OME (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0029" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Oral steroid versus no treatment, Outcome 1: Persistence of OME (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral steroid versus no treatment, Outcome 2: Persistence of OME (short‐term ‐ up to 3 months)" data-id="CD015255-fig-0030" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Oral steroid versus no treatment, Outcome 2: Persistence of OME (short‐term ‐ up to 3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral steroid versus no treatment, Outcome 3: Persistence of OME (medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0031" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Oral steroid versus no treatment, Outcome 3: Persistence of OME (medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 1: Change in hearing threshold (short‐term ‐ up to 3 months); ICC = 0.5" data-id="CD015255-fig-0032" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 1: Change in hearing threshold (short‐term ‐ up to 3 months); ICC = 0.5 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 2: Sensitivity analysis: change in hearing threshold (short‐term); ICC = 1.0" data-id="CD015255-fig-0033" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 2: Sensitivity analysis: change in hearing threshold (short‐term); ICC = 1.0 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 3: Sensitivity analysis: change in hearing threshold (short‐term); ICC = zero" data-id="CD015255-fig-0034" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 3: Sensitivity analysis: change in hearing threshold (short‐term); ICC = zero </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 4: Final hearing threshold (short‐term ‐ up to 3 months)" data-id="CD015255-fig-0035" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 4: Final hearing threshold (short‐term ‐ up to 3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 5: Disease‐specific quality of life (short‐term ‐ up to 3 months)" data-id="CD015255-fig-0036" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 5: Disease‐specific quality of life (short‐term ‐ up to 3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 6: Disease‐specific quality of life (medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0037" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 6: Disease‐specific quality of life (medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 7: Persistence of OME (very short‐term ‐ up to 6 weeks); ICC = 0.5" data-id="CD015255-fig-0038" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 7: Persistence of OME (very short‐term ‐ up to 6 weeks); ICC = 0.5 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 8: Sensitivity analysis: persistence of OME (very short‐term); ICC = 1.0" data-id="CD015255-fig-0039" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 8: Sensitivity analysis: persistence of OME (very short‐term); ICC = 1.0 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 9: Sensitivity analysis: persistence of OME (very short‐term); ICC = zero" data-id="CD015255-fig-0040" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 9: Sensitivity analysis: persistence of OME (very short‐term); ICC = zero </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 10: Persistence of OME (short‐term ‐ up to 3 months)" data-id="CD015255-fig-0041" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 10: Persistence of OME (short‐term ‐ up to 3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 11: Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0" data-id="CD015255-fig-0042" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 11: Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 12: Sensitivity analysis: persistence of OME (short‐term); ICC = zero" data-id="CD015255-fig-0043" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 12: Sensitivity analysis: persistence of OME (short‐term); ICC = zero </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 13: Persistence of OME (medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0044" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 13: Persistence of OME (medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 14: Adverse event: nasal bleeding (medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0045" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 14: Adverse event: nasal bleeding (medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nasal steroid versus placebo, Outcome 15: Generic health‐related quality of life (medium‐term ‐ up to 1 year)" data-id="CD015255-fig-0046" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Nasal steroid versus placebo, Outcome 15: Generic health‐related quality of life (medium‐term ‐ up to 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nasal steroid versus no treatment, Outcome 1: Final hearing threshold (very short‐term ‐ up to 6 weeks)" data-id="CD015255-fig-0047" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Nasal steroid versus no treatment, Outcome 1: Final hearing threshold (very short‐term ‐ up to 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nasal steroid versus no treatment, Outcome 2: Persistence of OME (very short‐term ‐ up to 6 weeks); ICC = 0.5" data-id="CD015255-fig-0048" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Nasal steroid versus no treatment, Outcome 2: Persistence of OME (very short‐term ‐ up to 6 weeks); ICC = 0.5 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nasal steroid versus no treatment, Outcome 3: Sensitivity analysis: persistence of OME (very short‐term); ICC = 1.0" data-id="CD015255-fig-0049" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Nasal steroid versus no treatment, Outcome 3: Sensitivity analysis: persistence of OME (very short‐term); ICC = 1.0 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nasal steroid versus no treatment, Outcome 4: Sensitivity analysis: persistence of OME (very short‐term); ICC = zero" data-id="CD015255-fig-0050" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Nasal steroid versus no treatment, Outcome 4: Sensitivity analysis: persistence of OME (very short‐term); ICC = zero </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nasal steroid versus no treatment, Outcome 5: Persistence of OME (short‐term ‐ up to 3 months); ICC = 0.5" data-id="CD015255-fig-0051" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Nasal steroid versus no treatment, Outcome 5: Persistence of OME (short‐term ‐ up to 3 months); ICC = 0.5 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nasal steroid versus no treatment, Outcome 6: Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0" data-id="CD015255-fig-0052" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Nasal steroid versus no treatment, Outcome 6: Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015255-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/urn:x-wiley:14651858:media:CD015255:CD015255-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nasal steroid versus no treatment, Outcome 7: Sensitivity analysis: persistence of OME (short‐term); ICC = zero" data-id="CD015255-fig-0053" src="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_t/tCD015255-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Nasal steroid versus no treatment, Outcome 7: Sensitivity analysis: persistence of OME (short‐term); ICC = zero </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/media/CDSR/CD015255/image_n/nCD015255-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015255-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral steroids compared to placebo for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Oral steroids compared to placebo for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children aged 6 months to 12 years with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> oral steroids <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With oral steroid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing ‐ return to normal hearing</p> <p>Follow‐up: 12 months (medium‐term)</p> <p>№ of participants: 332 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.14<br/>(0.97 to 1.33) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.7%<br/>(59.3 to 81.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6% more<br/>(1.8 fewer to 20.2 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroids probably result in little or no difference to the return to normal hearing at 12 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific quality of life (total OM8‐30, lower score is more favourable)</p> <p>Follow‐up: 12 months (medium‐term)</p> <p>№ of participants: 304 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disease‐specific quality of life was ‐0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 higher<br/>(0.2 lower to 0.34 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroids probably result in little or no difference in disease‐specific quality of life at 12 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence/persistence of OME</p> <p>Follow‐up: range 6 months to 12 months (medium‐term)</p> <p>№ of participants: 352 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Two studies indicated that persistence of OME may be reduced in those who received steroids, but the size of the effect was very different, ranging from a RR of 0.18 (persistence of OME in placebo group of 67%, compared to 12% of those receiving steroids) to a RR of 0.86 (persistence of OME in placebo group of 93.8% compared to 80.5% of those receiving steroids). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroids may reduce the persistence of OME in the medium term, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event: systemic corticosteroid side effects</p> <p>Follow‐up ranged from 12 days to 12 months</p> <p>№ of participants: 264 (3 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Without reporting directly on the incidence of systemic corticosteroid side effects, 3 studies provided information from which it may be reasonable to assume none occurred. One reported an asthma attack as the only serious adverse event and reported an adjusted OR of 0.59 (95% CI 0.28 to 1.27) for having no adverse effects (adjusted for site and age group at recruitment; data pooled across all follow‐up time points of 1, 2, 3, 4 and 5 weeks) (<a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a>). One study reported that none of the adverse events were classified as serious (<a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a>), and one further study reported that no significant adverse effects were seen in any study participant (<a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a>). Further information is provided in <a href="./full#CD015255-tbl-0002">Table 1</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the risk of systemic corticosteroid side effects with the use of oral steroids. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>OME:</b> otitis media with effusion; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for imprecision as the optimal information size (OIS) was not reached (&lt; 300 events) and the confidence interval crossed one decision threshold (RR 1.25). </p> <p><sup>2</sup>Downgraded one level for imprecision as the OIS was not reached (&lt; 400 participants). </p> <p><sup>3</sup>Downgraded two levels for imprecision as the OIS was not reached (&lt; 400 participants) and an estimate of the effect size was not possible, due to a narrative synthesis. </p> <p><sup>4</sup>Downgraded by one level for detection bias. </p> <p><sup>5</sup>Downgraded by two levels for imprecision as this was a narrative synthesis with zero reported events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral steroids compared to placebo for otitis media with effusion (OME) in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015255-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse event reporting: oral steroid</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event report</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Steroid type, dosage and duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Serious" or "severe" adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Only one serious adverse event was reported during the trial: one child in the placebo group had an asthma attack." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"One child reported fever and sore throat that was classified as a severe adverse event, but considered to have an unlikely association with treatment given. None of the adverse events were classified as serious." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Possible side‐effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 22/69; antibiotic + placebo: 17/66; RR 1.24 (95% CI 0.72 to 2.11) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tapering dose of oral dexamethasone for 13 days, starting at a max dose of 6 mg:</p> <p>0.15 mg/kg per day up to a maximum of 6 mg on days 1 and 2; 0.075 mg/kg per day (to a max of 3 mg/day) on days 3 and 4; 0.0375 mg/kg/day (to a max of 1.5 mg per day) on days 5, 6 and 7; 0.0375 mg/kg/day (to a max of 1.5 mg per day in children over 40 kg and 0.75 mg per day in children less than 40 kg) on days 9, 11 and 13 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant adverse effects were seen in any study participant."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone 1 mg per kg per day in 2 divided doses for a week followed by 0.5 mg per day for 1 week </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No adverse effect was reported from group C (oral steroid)."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of 6 mg betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No side effects of oral or intranasal steroids were reported in our patients"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted OR<sup>a</sup> 0.59 (95% CI 0.28 to 1.27) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 3/179; placebo: 1/170. RR 2.85 (95% CI 0.30 to 27.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 10/69; antibiotic + placebo: 6/66; RR 1.59 (95% CI 0.61 to 4.14) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 2/179; placebo: 0/170; Peto OR 7.07 (95% CI 0.44 to 113.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tired</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 1/179; placebo: 1/170; RR 0.95 (95% CI 0.06 to 15.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frustration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 0/179; placebo: 1/170; Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 1/69; antibiotic + placebo: 2/66; RR 0.48 (95% CI 0.04 to 5.15) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability and polyphagia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 1 mg/kg/day for the first 2 days in a divided dose, 0.75 mg/kg/day for the next 2 days and 5 to 10 mg/day as a single morning dose for the remaining 3 days. If partial clearing another week of prednisone 5 to 10 mg in a single morning dose on alternate days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Only one child treated with the prednisone/sulfa manifested symptoms of irritability and polyphagia; this was the only complication of therapy in the 40 children treated with corticosteroids." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleepwalking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 1/179; placebo: 0/170; Peto OR 7.03 (95% CI 0.14 to 354.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No symptoms of changes in behaviour and mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt;5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted OR<sup>a</sup> 0.76 (95% CI 0.49 to 1.19) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (95% CI 0.16 to 3.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 8/69; antibiotic + placebo: 4/66; RR 1.91 (95% CI 0.60 to 6.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.13 (95% CI 0.01 to 2.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.27 (95% CI 0.29 to 5.57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.5 to 1.0 mg/kg/dose twice a day for 7 days (plus antibiotic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No side effects were noted in patients treated with prednisone and/or TMP/SMZ (antibiotic) other than one patient with a self limited episode of vomiting. The relationship of the vomiting to the TMP/SMZ and prednisone was unclear." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 1/59; antibiotic + placebo: 3/61 RR 0.34 (95% CI 0.04 to 3.22) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 3/69; antibiotic + placebo: 2/66; RR 1.43 (95% CI 0.25 to 8.32) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 1/179; placebo: 0/170; Peto OR 7.03 (95% CI 0.14 to 354.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stomach pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 2/59; antibiotic + placebo: 2/61; RR 1.03 (95% CI 0.15 to 7.10) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 1/69; antibiotic + placebo: 2/66; RR 0.48 (95% CI 0.04 to 5.15) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 2/179; placebo: 2/170; RR 0.95 (95% CI 0.14 to 6.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 4/59; antibiotic + placebo: 2/61; RR 2.07 (95% CI 0.39 to 10.87) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loose stools</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 2/59; antibiotic + placebo: 2/61; RR 1.03 (95% CI 0.15 to 7.10) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 4/69; antibiotic + placebo: 1/66; RR 3.83 (95% CI 0.44 to 33.35) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 0/59; antibiotic + placebo: 1/161; Peto OR 0.14 (95% CI 0.00 to 7.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 1/179; placebo: 1/170; RR 0.95 (95% CI 0.06 to 15.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No symptoms of nausea, vomiting or indigestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted OR<sup>a</sup> 0.67 (95% CI 0.4 to 1.11) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dermatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of a betamethasone tablet (6 mg) on the morning of day 10 (plus antibiotic for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid + antibiotic: 1/59; antibiotic + placebo: 0/61; Peto OR 7.64 (95% CI 0.15 to 385.43) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 0/69; antibiotic + placebo: 1/66; Peto OR 0.13 (95% CI 0.00 to 6.52) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash, pox or scarlet fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.13 (95% CI 0.01 to 2.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flushed cheeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.03 (95% CI 0.14 to 354.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg given twice a day on days 1 through 10 (total daily dose 1 mg/kg, maximum 30 mg/day), then given once a day on days 11 through 14 (total daily dose 0.5 mg/kg, maximum 15 mg/day) plus antibiotic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During weeks 1 and 2: oral steroid + antibiotic: 4/69; antibiotic + placebo: 2/66; RR 1.91 (95% CI 0.36 to 10.10) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phlegmy cough, cold, sneezing, temperature, nosebleed, conjunctivitis, itchy eyes, or generally unwell </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.32 (95% CI 0.70 to 15.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parotitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain on touch or earache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (95% CI 0.06 to 15.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parent states child not hearing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 0/179; placebo: 1/170. Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finger infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 0/179; placebo: 1/170. Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Knee pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 2 to 5 years: a single daily dose of 4 tablets (20 mg of prednisolone) for 7 days </p> <p>Aged &gt; 5 years: a single daily dose of 6 tablets (30 mg of prednisolone) for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral steroid: 0/179; placebo: 1/170. Peto OR 0.13 (95% CI 0.00 to 6.48)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Adjusted for site and child’s age group at recruitment (2 to 5 years and 6 to 8 years), data pooled across all follow‐up time points (1, 2, 3, 4 and 5 weeks). </p> <p>CI: confidence interval; OR: odds ratio; RR: risk ratio</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse event reporting: oral steroid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015255-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral steroids compared to no treatment for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Oral steroids compared to no treatment for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children aged 6 months to 12 years with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> oral steroids <br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without oral steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With oral steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hearing</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data were identified for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐specific quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data were identified for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence/persistence of OME (3 to 9 months ‐ medium‐term)</p> <p>№ of participants: 258 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/>(0.89 to 1.17) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.5%<br/>(65 to 85.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% more<br/>(8 fewer to 12.4 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that oral steroids may result in little or no difference in the persistence of OME in the medium term, when compared with no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event: systemic corticosteroid side effects</p> <p>Follow‐up: 1 month</p> <p>№ of participants: 40 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>One trial reported that none of 40 participants given oral prednisolone in a tapering course over 2 weeks reported adverse effects over 1 month of follow‐up (<a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a>). Further information is available in <a href="./full#CD015255-tbl-0002">Table 1</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of a 2‐week tapering course of prednisolone on the risk of systemic corticosteroid side effects at 1 month of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for a risk of performance bias. </p> <p><sup>2</sup>Downgraded by one level for imprecision, as the optimal information size (OIS) was not reached (&lt; 300 events). </p> <p><sup>3</sup>Downgraded by two levels for a risk of performance and detection bias (arising from lack of blinding and brief follow‐up). </p> <p><sup>4</sup>Downgraded by two levels for very serious imprecision, due to a narratively reported outcome, with zero reported cases amongst a small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral steroids compared to no treatment for otitis media with effusion (OME) in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015255-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Topical (intranasal) steroids compared to placebo for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Topical (intranasal) steroids compared to placebo for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children aged 6 months to 12 years with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> topical (intranasal) steroids <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without topical steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With topical steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing ‐ hearing threshold; assumed ICC = 0.5</p> <p>Follow‐up: 2 months (short‐term)</p> <p>№ of participants: 78 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in hearing threshold (short‐term), ICC = 0.5, without nasal steroid was ‐7.6 dB </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 dB lower<br/>(6.05 lower to 5.45 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of nasal steroids on change in hearing threshold at 2 months, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific quality of life (total OM8‐30 score, lower score is more favourable)</p> <p>Follow‐up: 9 months (medium‐term)</p> <p>№ of participants: 82<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disease‐specific quality of life (medium‐term) without nasal steroid was 2.87 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.05 higher<br/>(0.36 lower to 0.46 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that nasal steroids result in little to no difference in disease‐specific quality of life at 9 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence/persistence of OME</p> <p>Follow‐up: up to 1 year (medium‐term)</p> <p>№ of participants: 206 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Two studies reported this outcome, but the results were conflicting. One study showed some benefit to intranasal steroids, whilst the other showed a potential increase in the number of children with persistent OME. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of nasal steroids on persistence of OME at up to 12 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event: systemic corticosteroid side effects</p> <p>Follow‐up: range 9 months to 2 years</p> <p>№ of participants: 157 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Without reporting directly on the incidence of systemic corticosteroid side effects, 2 studies provided information from which it may be reasonable to assume none occurred. One study reported that there were no serious adverse events and that growth rate was unaffected over 2 years (<a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a>). A second study reported that there were no serious adverse events, suspected serious adverse reactions or related hospitalisations (<a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the risk of systemic corticosteroid side effects with nasal steroids over 2 years. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>ICC:</b> intracluster correlation coefficient; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for risk of bias, due to the potential for selection bias, detection bias and reporting bias. </p> <p><sup>2</sup>Downgraded by one level for imprecision, as the optimal information size (OIS) was not reached (&lt; 400 participants). </p> <p><sup>3</sup>Downgraded by one level due to the risk of attrition bias. </p> <p><sup>4</sup>Downgraded by one level for risk of bias, due to concerns over reporting bias and attrition bias. </p> <p><sup>5</sup>Downgraded by two levels for imprecision, as this was a narrative synthesis (therefore no estimate of effect could be provided) and the OIS was not reached (&lt; 300 events). </p> <p><sup>6</sup>Downgraded by two levels for very serious imprecision as this is a narrative synthesis, with zero events in either of two studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Topical (intranasal) steroids compared to placebo for otitis media with effusion (OME) in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015255-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topical (intranasal) steroids compared to no treatment for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Topical (intranasal) steroids compared to no treatment for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children aged 6 months to 12 years with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> topical (intranasal) steroids<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without topical steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With topical steroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing ‐ hearing threshold (air‐bone gap, very short‐term); assumed ICC = 0.5</p> <p>Follow‐up: 4 weeks</p> <p>№ of participants: 168 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean air‐bone gap without nasal steroid was 9.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.95 lower<br/>(3.85 lower to 0.05 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical (intranasal) steroids may make little or no difference to final hearing threshold at 4 weeks when compared to no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence/persistence of OME (short‐term); assumed ICC = 0.5</p> <p>Follow‐up: range 6 weeks to 8 weeks</p> <p>№ of participants: 134 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/>(0.57 to 0.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.5%<br/>(46.3 to 73.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8% fewer<br/>(34.9 fewer to 7.3 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of topical (intranasal) steroids on presence/persistence of OME at 6 to 8 weeks, when compared to no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event: systemic corticosteroid side effects</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported adverse events in sufficient detail to establish whether or not systemic corticosteroid side effects occurred. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>ICC:</b> intracluster correlation coefficient; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for risk of bias, due to concerns over performance and detection bias. </p> <p><sup>2</sup>Downgraded by one level for imprecision, as the optimal information size (OIS) was not reached (&lt; 400 participants). </p> <p><sup>3</sup>Downgraded by two levels for risk of bias, due to concerns over performance, detection and selection bias. </p> <p><sup>4</sup>Downgraded by one level for imprecision, as the OIS was not reached (&lt; 300 events) and the confidence interval crossed one decision threshold (RR 0.80). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topical (intranasal) steroids compared to no treatment for otitis media with effusion (OME) in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015255-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RCTs identified through Cochrane Crowd and the RCT classifier</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Possible RCTs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rejected</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Known assessments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT classifier</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1514</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane Crowd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1313</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2877</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RCTs identified through Cochrane Crowd and the RCT classifier</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015255-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concomitant treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 12 years with OME (n = 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone furoate 50 µg per nostril per day for 1 month</p> <p>or</p> <p>Oral prednisone (1 mg/kg/day) for 1 week, then 0.5 mg/kg/day for a further week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study arm assessed antibiotics and antihistamine nasal decongestants (not relevant for this review) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0002" title="AhmedMR , EldeebWE . Effectiveness of mometasone furoate nasal spray on tympanometric results and hearing loss in children with otitis media with effusion. Egyptian Journal of Otolaryngology2022;38(1):32. [CENTRAL: CN-02518321] ">Ahmed 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 12 years with bilateral OME (n = 168)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone furoate spray, 50 µg/puff, 2 puffs per nostril once daily for 1 month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in both groups also received amoxicillin and clavulanic acid (90 g/kg/day) for 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0003" title="BaratiB , OmraniMR , OkhovatAR , KelishadiR , HashemiM , HassanzadehA , et al. Effect of nasal beclomethasone spray in the treatment of otitis media with effusion. Journal of Research in Medical Sciences2011;16(4):509-15. [CENTRAL: CN-01777185] [EMBASE: 361828890] [PMID: 22091267]">Barati 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years with OME (n = 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal beclomethasone, 1 puff per nostril (dose not given) for 4 weeks. Twice daily for children aged 1 to 5 years, 3 times daily for children aged 6 to 10 years. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants also received amoxicillin 50 mg/kg/day for 1 week and decongestant (nasal saline spray and pseudoephedrine syrup) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0004" title="BeighZ , LattooM , YousufA , PamporiR . Topical nasal steroids for hearing loss associated with otitis media with effusion in children. Indian Journal of Otology2013;19(3):132-5. [CENTRAL: CN-00873772] [EMBASE: 2013602416]">Beigh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 8 years with OME (n = 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone (dose and frequency not stated) for 3 weeks, then a tapering dose for a further 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0005" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with middle ear effusion for ≥ 6 weeks despite at least 2 courses of antibiotics (n = 68). Mean age 2.5 to 3 years (range 5 months to 12 years). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisone 0.5 to 1.0 mg/kg/dose twice daily for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trimethoprim‐sulfamethoxazole 5 mg/kg/dose twice daily for 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with unresolved OME by 2‐week follow‐up crossed over to the alternative regimen, and therefore some participants received both interventions. These data were not included in the review. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with at least 3 months of bilateral OME (n = 62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone furoate 50 µg/nostril twice daily for 8 weeks, then reduced to alternate day dosing for a further 16 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (nasal saline spray), administered with the same frequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants had adenoid hypertrophy, and had failed to respond to "previous medical therapy" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0007" title="AkyolMU , CengelS . The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow-up. In: Proceedings of the 9th International Conference on Pediatric Otorhinolaryngology (ESPO); 2006 Jun 18-21; Paris, France. 2006. [ABSTRACT NUMBER: 329] [CENTRAL: CN-00597474] CengelS , AkyolMU . The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. International Journal of Pediatric Otorhinolaryngology 2006 Apr;70(4):639-45. [CENTRAL: CN-00561141] [EMBASE: 2006094358] [PMID: 16169093]">Cengel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 3 to 15 years with at least 3 months of bilateral or unilateral OME (n = 63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intranasal mometasone furoate 100 µg daily, 1 spray in each nostril once a day for 6 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0008" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 months to 12 years with unilateral or bilateral OME (n = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre university hospital in South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone 1 mg/kg/day for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received 2 weeks of amoxicillin‐clavulanic acid (2 groups also received antihistamine for 2 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data from the relevant arms have been pooled for analysis, to allow a comparison of those who received steroids to those who did not </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0009" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . A placebo-controlled study of cetixime and the combination of cefixime and betamethasone in children with secretory otitis media. In: Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media, Japan, Mar 31-Apr 3, 1993. 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with unilateral or bilateral OME of at least 3 months duration (n = 142) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre hospital in Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose of 6 mg betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received cefixime 8 mg/kg/day for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Longer follow‐up was reported, but only for a subset of participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0010" title="HusseinA , FathyH , AminSM , ElsisyN . Oral steroids alone or followed by intranasal steroids versus watchful waiting in the management of otitis media with effusion. Journal of Laryngology and Otology2017;131(10):907-13. [CENTRAL: CN-01412927] [EMBASE: 618740433] [PMID: 28807086]">Hussein 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 11 years with bilateral OME (n = 202)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre hospital in Saudi Arabia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seven days of oral prednisolone, 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0011" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with unilateral or bilateral OME (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre hospital in Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide intranasal spray, 200 µg/day for 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received ampicillin/sulbactam 25 mg/kg/day for 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0012" title="KhanamA , AkhtarG , RahmanMA , ChowdhuryN . Efficacy of mometasone furoate nasal spray with oral montelukast in the treatment of otitis media with effusion with or without adenoid hypertrophy and atopic diseases. Bangladesh Journal of Medical Science2022;21(4):836-41. [CENTRAL: CN-02463601] [EMBASE: 2017966228]">Khanam 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with bilateral OME for at least 3 months (n = 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre tertiary hospital in Bangladesh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 100 µg per nostril per day for 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline spray, used with the same frequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study arm assessed montelukast (not relevant for this review)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0013" title="LambertPR . Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study. Otolaryngology - Head and Neck Surgery1986;95(2):193-9. [CENTRAL: CN-00048297] [PMID: 3108758]LambertPR . Treatment of chronic middle-ear effusion with oral steroids - a double-blind crossover study. Otolaryngology - Head and Neck Surgery1985;SI:50. [CENTRAL: CN-02469807] ">Lambert 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 15 years with OME (n = 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from an ENT clinic in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone once daily for 14 days according to the following schedule: 1.5 mg/kg/day for 4 days; 0.75 mg/kg/day for 4 days; 5 mg or 10 mg (depending on the child’s weight) every other day for 6 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo syrup, administered in the same way</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received either 125 mg or 250 mg amoxicillin 3 times daily for 14 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 to 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some participants received a second course of steroids (if resolution had started but was not complete by 10 days </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 14 years with uni‐ or bilateral OME (n = 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial from a private ENT clinic in Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclomethasone 100 µg per nostril twice daily for one month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0015" title="MackninML , JonesPK , MakninML . Oral dexamethasone for treatment of persistent middle ear effusion. Pediatrics1985;75(2):329-35. [CENTRAL: CN-00036813] [PMID: 4038553]">Macknin 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (mean age 3 to 4 years) with OME for at least 3 weeks (n = 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial from a paediatric department of a hospital in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral dexamethasone, tapering dose for 13 days (starting dose 0.15 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some children in this trial had a middle ear effusion persisting after an episode of AOM </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0016" title="MandelEM , CasselbrantML , RocketteHE , FiremanP , Kurs-LaskyM , BluestoneCD . Systemic steroid for chronic otitis media with effusion in children. Pediatrics2002;110(6):1071-80. [CENTRAL: CN-00411840] [PMID: 12456902]">Mandel 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 9 years with uni‐ or bilateral middle ear effusion (n = 144)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial from a children's hospital in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone syrup 0.5 mg/kg twice daily for 10 days, then once daily for a further 4 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 40 mg/kg/day in 3 divided doses for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0017" title="NiedermannLG , Walter-BucholtzV , JabalayT , NiedermanLG , JabalayT . A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , NelsonJD , editors(s). Recent Advances in Otitis Media with Effusion. Philadelphia: B.C. Decker Inc, 1984:273-5. [CENTRAL: CN-00449353] ">Niederman 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged ≤ 2 years with OME for at least 8 weeks (n = 26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial from a hospital in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tapering dose of oral dexamethasone for 13 days, starting at a dose of 0.15 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0018" title="FrancisNA , Cannings-JohnR , WaldronCA , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial. Lancet2018;392(10147):557-68. [CENTRAL: CN-01630080] [EMBASE: 2001028718] [PMID: 30152390]FrancisNA , WaldronCA , Cannings-JohnR , Thomas-JonesE , WinfieldT , ShepherdV , et al. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT. Health Technology Assessment2018;22(61):1-114. [CENTRAL: CN-01911294] [EMBASE: 625077854] [PMID: 30407151]ISRCTN49798431. A randomised double blind placebo controlled clinical trial using oral steroids for the resolution of otitis media with effusion (OME) in children [Oral steroids for resolution of otitis media with effusion in children]. https://www.isrctn.com/ISRCTN49798431 (first received 7 December 2012). [CENTRAL: CN-00858707] Waldron C-A, Thomas-JonesE , HarrisD , ShepherdV , Cannings-JohnR , HoodK , et al. Recruitment to oral steroids for the resolution of otitis media with effusion in children (OSTRICH) study: challenges of a randomised controlled trial in secondary care sites across Wales and England. Trials2015;16(Suppl 2):P119. [CENTRAL: CN-01474441] [EMBASE: 614954045]WaldronCA , Thomas-JonesE , Cannings-JohnR , HoodK , PowellC , RobertsA , et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials2016;17(1):115. [CENTRAL: CN-01259952] [EMBASE: 20160543347] [PMID: 26931619]">OSTRICH 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 8 years with bilateral OME for at least 3 months (n = 380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre trial conducted at 20 sites across the UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7‐day course of oral soluble prednisolone (20 mg per day for children aged 2 to 5, 30 mg per day for those aged &gt; 5 years) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0019" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology - Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 3 to 8 years with OME for at least 2 months (n = 150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted in Israel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 day tapering dose of oral prednisolone, with initial dose of 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 50 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0020" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 7 months to 11 years with OME (n = 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted in Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone 1 mg/kg/day, given as a tapering dose over 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfadiazine (18.5 mg/kg/day) and trimethoprim (6 mg/kg/day) for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that all participants received myringotomy at the start of the trial and at any follow‐up visit where an effusion was detected </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0021" title="NCT02541760. Monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children. https://clinicaltrials.gov/show/NCT02541760 (first received April 2014). [CENTRAL: CN-01104444] RahmatiMB , SafdarianF , ShirouiB , ZareS , SadeghiN . Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: a randomized controlled trial. Electronic Physician2017;9(7):4890-4. [CENTRAL: CN-01412230] [PMID: 28894551]">Rahmati 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 6 years with OME (n = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted in Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal mometasone, 1 puff per nostril daily for 1 month (dose not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0022" title="SaffarM . The effect of prednisolone on middle ear fluid absorption. Journal of Mazandaran University of Medical Sciences2001;11(33):14-9. ">Saffar 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 10 with OME (n = 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted in Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone 1 mg/kg/day for 7 days, then tapered over next 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 8 years with OME for at least 3 months (n = 200)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre trial conducted from a specialist OME clinic in the UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone propionate nasal spray 50 µg per nostril twice daily for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some children in the trial also received autoinflation as an additional, background treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No efficacy data were useable from this study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0024" title="SchwartzRH , PugleseJ , SchwartzDM . Use of a short course of prednisone for treating middle ear effusion. A double-blind crossover study. Annals of Otology, Rhinology &amp; Laryngology. Supplement1980;89(Suppl 68):296-300. [CENTRAL: CN-00024099] [PMID: 6778331]SchwartzRH , PugleseJ . Use of a short course of prednisone for treating middle-ear effusions - double-blind crossover study. Journal of Allergy and Clinical Immunology1979;3:201-1. ">Schwartz 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years with OME for at least 3 weeks (n = 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two‐centre trial from private practices in the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral prednisolone, 1 mg/kg/day to start, with a tapering does over 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfisoxazole 50 mg/kg/day for 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some participants received additional prednisolone (5 to 10 mg on alternate days for 1 week). Unclear how many participants this applies to. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0025" title="StuartJE . A randomised controlled trial of nasal beclomethasone spray in ear disease in Aboriginal children. Aboriginal Torres Strait Island Health Information Bulletin1995;21:77. [CENTRAL: CN-02284861] ">Stuart 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (mean 4.5 years) with uni‐ or bilateral OME (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal beclomethasone twice daily for 5 to 8 weeks (dose not given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that 2 studies are reported in the same publication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 11 years with bilateral OME (n = 217)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre trial from the UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal mometasone furoate 50 µg per nostril once daily for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015255-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse event reporting: intranasal steroid</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event report</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Steroid type, dosage and duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No serious adverse events"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone propionate aqueous nasal spray 50 µg per spray, 1 puff per nostril twice daily for 2 weeks (2 puffs per nostril twice daily for children over 35 kg), i.e. total daily dose 200 µg (or 400 µg) initially; then reduced to 1 puff per nostril (100 µg) once daily. “The children were asked to use this on a regular basis”. “Those who reported spray use on at least 3 days a week remained in the study” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over 2 years: "There were no serious adverse events in this study."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No serious adverse events, suspected serious adverse reactions or related hospitalisations occurred during the study." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Reported side‐effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: Nasal steroid: 45/96; placebo: 35/98; RR 1.31 (95% CI 0.93 to 1.84).</p> <p>At 3 months: nasal steroid: 29/86; placebo: 23/86; RR 1.26 (95% CI 0.80 to 1.99)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclomethasone dipropionate nasal spray administered twice in each nostril (100 µg per nostril) twice a day, for a total of 400 µg daily, for 1 month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Apart from that (the child’s response to the power of the nasal spray) complications in the use of the spray were not noticed, especially no signs of mycosis or atrophy of the nasal mucosa occurred." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No effect on growth"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone propionate (FP) aqueous nasal spray 50 µg per spray, 1 puff per nostril twice daily for 2 weeks (2 puffs per nostril twice daily for children over 35 kg), i.e. total daily dose 200 µg (or 400 µg) initially; then reduced to o1ne puff per nostril (100 µg) once daily. “The children were asked to use this on a regular basis”. “Those who reported spray use on at least 3 days a week remained in the study” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over 2 years: "The plots of growth rate (not presented) indicated a uniform increase in height over the time period, independent of treatment. The mixed model fitted indicated no significant difference in growth rates between those children receiving FP and those given placebo on either method of analysis." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nosebleed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0001" title="AcharyaA , PokharelB , PanditSB , BartaulaS . Efficacy and cost-effectiveness analysis of steroid in treatment of otitis media with effusion (OME) in children: a randomized trial. Journal of Gandaki Medical College Nepal2020;13(2):111-5. [CENTRAL: CN-02469808] NCT03590912. Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion [Efficacy and cost analysis of steroid spray in treatment of otitis media with effusion (OME) compared to that of antibiotic, antihistaminic, and nasal decongestant]. Https://clinicaltrials.gov/show/nct03590912 (first received 18 July 2018). [CENTRAL: CN-01625711] ">Acharya 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril once a day for 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“One case (2.5%) from group B (nasal spray) reported blood tinged nasal discharge which was managed with nasal ointment and counselling regarding proper way of using nasal spray. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0006" title="BhargavaR , ChakravartiA . A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. American Journal of Otolaryngology2014;35(6):766-70. [CENTRAL: CN-01036886] [EMBASE: 2014790206] [PMID: 25151658]">Bhargava 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial treatment of 2 puffs of mometasone furoate nasal spray (50 µg/puff) in each nostril once a day (a total of 200 µg/day) for first 8 weeks, followed by 2 puffs in each nostril on alternate days for 16 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal saline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal steroid: 2/30; nasal saline: 3/32; RR 0.71 (95% CI 0.13 to 3.97; <a href="./references#CD015255-fig-0045" title="">Analysis 3.14</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0023" title="ScaddingG , RajputK , ParikhA , HilssS , JanszJA , DarbyYC , et al. Double blind, placebo-controlled study of flixonase with and without otovent in the treatment of otitis media with effusion. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO); 2002 Sep 11-14; Oxford, UK. 2002:92-3. [ABSTRACT NUMBER: 21.04] [CENTRAL: CN-00431597] ScaddingGK , DarbyYC , JanszAJ , RichardsD , TateH , HillsS , et al. Double-blind, placebo controlled randomised trial of medical therapy in otitis media with effusion. Advances in Life Sciences and Health2014;1:2. [CENTRAL: CN-01043521] ">Scadding 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone propionate aqueous nasal spray 50 µg per spray, 1 puff per nostril twice daily for 2 weeks (2 puffs per nostril twice daily for children over 35 kg), i.e. total daily dose 200 µg (or 400 µg) initially; then reduced to 1 puff per nostril (100 µg) once daily. “The children were asked to use this on a regular basis”. “Those who reported spray use on at least 3 days a week remained in the study” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Minor adverse events were recorded, but none was of sufficient severity to cause cessation of the treatment or withdrawal from the trial. The commonest was minor epistaxis which occurred in fewer than 10% of subjects." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: nasal steroid: 8/96; placebo: 7/98; RR 1.17 (95% CI 0.44 to 3.09)</p> <p>At 3 months: nasal steroid: 10/86; placebo: 6/86; RR 1.67 (95% CI 0.63 to 4.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stinging in the nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: nasal steroid: 9/96; placebo: 10/98; RR 0.92 (95% CI 0.39 to 2.16)</p> <p>At 3 months: nasal steroid: 9/86; placebo: 9/86; RR 1.00 (95% CI 0.42 to 2.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry throat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: nasal steroid: 13/96; placebo: 14/98; RR 0.95 (95% CI 0.47 to 1.91)</p> <p>At 3 months: nasal steroid: 10/86; placebo: 7/86; RR 1.43 (95% CI 0.57 to 3.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0026" title="ISRCTN38988331. A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care. https://www.isrctn.com/ISRCTN38988331 (first received 9 October 2003). [CENTRAL: CN-01013264] PetrouS , DakinH , AbangmaG , BengeS , WilliamsonI . Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value in Health2010;13(5):543-51. [CENTRAL: CN-00771882] [PMID: 20345546]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technology Assessment (Winchester, England)2009;13(37):1-144. [CENTRAL: CN-01705886] [EMBASE: 2009594755] [PMID: 19671372]WilliamsonI , BengeS , BartonS , PetrouS , LetleyL , FaseyN , et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ (Clinical Research Ed.) 2009 Dec 16;339(7737):b4984. [CENTRAL: CN-00732682] [EMBASE: 358169071] [PMID: 20015903]">Williamson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone furoate 50 µg in each nostril (total daily dose 100 µg) once daily for 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1 month: nasal steroid: 23/96; placebo: 19/98; RR 1.24 (95% CI 0.72 to 2.12)</p> <p>At 3 months: nasal steroid: 19/86; placebo: 11/86; RR 1.73 (95% CI 0.88 to 3.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intolerance of administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015255-bbs2-0014" title="LildholdtT , KortholmB . Beclomethasone nasal spray in the treatment of middle-ear effusion - a double-blind study. International Journal of Pediatric Otorhinolaryngology1982;4(2):133-7. [CENTRAL: CN-00029127] [PMID: 6752070]">Lildholdt 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclomethasone dipropionate nasal spray administered twice in each nostril (100 µg per nostril) twice a day, for a total of 400 µg daily, for 1 month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This produced a rather powerful spray, and often a mist would appear through the open mouth; thus the spray reached the rhinopharynx, but many children were scared initially and did not enter the study. In a few cases the treatment was discontinued for that reason." </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse event reporting: intranasal steroid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015255-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analysis result (RR and 95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis result (RR and 95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Oral steroid versus placebo</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 Persistence of OME (very short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.51 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.82 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 Persistence of OME (very short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.51 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies with any concern over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.48 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 (0.50 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.67 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Oral steroid versus no treatment</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 Persistence of OME (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.89 to 1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.90 to 1.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Nasal steroid versus placebo</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.10 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.51 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.69 to 1.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.10 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.51 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies with any concern over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.63 to 1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Nasal steroid versus no treatment</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2 Persistence of OME (very short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.44 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (0.50 to 0.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2 Persistence of OME (very short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.44 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.46 to 1.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.57 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.57 to 0.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.57 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies with any concern over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.50 to 0.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.57 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding studies at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 [0.55 to 1.16)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/full#CD015255-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015255-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral steroid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Normal hearing (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Normal hearing (very short‐term ‐ up to 6 weeks, adjusted OR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Normal hearing defined as complete improvement in air‐bone gap (short‐term ‐ up to 3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Normal hearing (medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.97, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Hearing threshold (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Hearing threshold (difference in adjusted mean, very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Disease‐specific quality of life (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Disease‐specific quality of life (medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Persistence of OME (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.51, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.23, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Persistence in one or both affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.24, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Persistence defined as effusion in all affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Persistence defined as effusion in either or both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.63, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Sensitivity analysis: persistence of OME (very short‐term); persistence in all affected ears (Berman 1990) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.50, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.23, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Persistence in one or both affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.70, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Persistence defined as effusion in all affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.36, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 Persistence defined as effusion in either or both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.63, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Sensitivity analysis: persistence of OME (very short‐term); effusion in both ears (Niederman 1984) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.51, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.23, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Persistence in one or both affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.24, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Persistence defined as effusion in all affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 Persistence defined as effusion in either or both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.62, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.5 Persistence defined as effusion in both ears (whether affected at baseline or not) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.37, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Persistence of OME (short‐term ‐ up to 3 months); ICC = 0.5 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.50, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Persistence in any ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.20, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Persistence defined as effusion in the worst ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.52, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Persistence in any ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.19, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Persistence defined as effusion in the worst ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Sensitivity analysis: persistence of OME (short‐term); ICC = zero <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.47, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Persistence in any ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.19, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Persistence defined as effusion in the worst ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Sensitivity analysis: persistence of OME (short‐term); persistence in all affected ears (Macknin 1985) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.47, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Persistence defined as effusion in any ear </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.20, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Persistence defined as effusion in the worst ear </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 Persistence defined as effusion in all affectedears </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Persistence of OME (medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Persistence defined as effusion in both affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.79, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.06, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Acute otitis media (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.31, 3.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Generic health‐related quality of life (PedsQL, very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Generic health‐related quality of life (PedsQL, medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Generic health‐related quality of life (HU13, very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.70, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Generic health‐related quality of life (HU13, medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.79, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Subgroup analysis: normal hearing: allergy versus none (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.92, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 Allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.81, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 No allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.84, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Subgroup analysis: persistence of OME: allergy versus none (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.59, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.1 Allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.70, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.2 No allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.50, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Subgroup analysis: persistence of OME: age &lt; 4 versus ≥ 4 (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.64, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 Age &lt; 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.44, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.2 Age ≥ 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.62, 1.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral steroid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015255-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral steroid versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Persistence of OME (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Persistence of OME (short‐term ‐ up to 3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Persistence in one or both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Persistence of OME (medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.76, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Persistence in one or both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.87, 1.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral steroid versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015255-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Nasal steroid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Change in hearing threshold (short‐term ‐ up to 3 months); ICC = 0.5 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐6.05, 5.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Sensitivity analysis: change in hearing threshold (short‐term); ICC = 1.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐6.80, 6.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Sensitivity analysis: change in hearing threshold (short‐term); ICC = zero <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐5.21, 4.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Final hearing threshold (short‐term ‐ up to 3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.95 [‐17.32, ‐12.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Disease‐specific quality of life (short‐term ‐ up to 3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Disease‐specific quality of life (medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Persistence of OME (very short‐term ‐ up to 6 weeks); ICC = 0.5 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.80, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Sensitivity analysis: persistence of OME (very short‐term); ICC = 1.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Sensitivity analysis: persistence of OME (very short‐term); ICC = zero <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.83, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Persistence of OME (short‐term ‐ up to 3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Analysis per child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.33, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Analysis per ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.83, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.50, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Analysis per child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.33, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Analysis per ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.83, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Sensitivity analysis: persistence of OME (short‐term); ICC = zero <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.51, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 Analysis per child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.33, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 Analysis per ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.89, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Persistence of OME (medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.2 Persistence in both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Adverse event: nasal bleeding (medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Generic health‐related quality of life (medium‐term ‐ up to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Nasal steroid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015255-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Nasal steroid versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Final hearing threshold (very short‐term ‐ up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.95 [‐3.85, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Persistence of OME (very short‐term ‐ up to 6 weeks); ICC = 0.5 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.44, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Persistence in any or both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.61, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.29, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Persistence in any affected ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Sensitivity analysis: persistence of OME (very short‐term); ICC = 1.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.44, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Persistence in any or both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.58, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.29, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Persistence in any affected ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Sensitivity analysis: persistence of OME (very short‐term); ICC = zero <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Persistence in any or both ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Persistence undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.29, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Persistence in any affected ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Persistence of OME (short‐term ‐ up to 3 months); ICC = 0.5 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Persistence in affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Sensitivity analysis: persistence of OME (short‐term); ICC = 1.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.54, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Persistence in affected ears. ICC 1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.54, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Sensitivity analysis: persistence of OME (short‐term); ICC = zero <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.60, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Persistence in affected ears. ICC zero</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.60, 0.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Nasal steroid versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015255.pub2/references#CD015255-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015255.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015255-note-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015255-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015255-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015255-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD015255-note-0018">Magyar</a> </li> <li class="section-language"> <a class="" href="ms#CD015255-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD015255-note-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015255-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015255-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015255\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015255\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015255\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015255\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015255\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015255.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015255.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015255.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015255.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015255.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716921352"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015255.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716921355"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015255.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dab495bc9f3f1',t:'MTc0MDcxNjkyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 